Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

DR info

Clinical trials : 576 / Drugs : 519 - (DrugBank : 130) / Drug target genes : 108 - Drug target pathways : 219

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)

100 MG AP1189
   SynAct Pharma Aps
      2020   Phase 2   NCT04456816   Denmark
7-valent pneumococcal conjugate vaccine
   National and Kapodistrian University of Athens
      2009   Phase 4   NCT01346007   Greece
Abatacept
   Bristol-Myers Squibb
      2016   Phase 2   NCT02592798   United States
   Bristol-Myers Squibb Company
      -   Phase 2   EUCTR2015-005450-36-Outside-EU/EEA   United States
Acei, SGLT-2I
   Mansoura University
      2023   Phase 4   NCT06417320   Egypt
Acei/ARB
   Department of Nephrology, Sichuan Provincial People's Hospital
      2021   -   ChiCTR2100048382   China
   General Hospital of Ningxia Medical University
      2025   -   ChiCTR2500103410   China
   Institute of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
      2006   -   ChiCTR-OPN-17012789   China
   The First Affiliated Hospital of the People's Liberation Army Air Force University of Military Medicine
      2024   -   ChiCTR2400086359   China
Acei/ARB+ finerenone
   First Affiliated Hospital, Sun Yat-Sen University
      2024   Phase 4   NCT06573411   China
Acetaminophen
   Hoffmann-La Roche
      2021   Phase 3   NCT04629248   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russia;Spain;Turkey (Türkiye);Ukraine;United States
Acetaminophen/ paracetamol
   Hoffmann-La Roche
      2023   Phase 3   NCT05627557   Belgium;Brazil;China;France;Germany;Italy;Japan;Poland;Spain;Turkey (Türkiye);United States
Acetazolamide and hydrochlorothiazide followed BY furosemide
   Shiraz University of Medical Sciences
      2015   Phase 4   NCT02427880   -
Acth
   Emory University
      2014   Phase 3   NCT02132195   United States
   Mayo Clinic
      2009   Phase 1   NCT00805753   Canada;United States
   Southeast Renal Research Institute
      2009   Phase 4   NCT01028287   United States
Acthar
   Greater Boston Medical Associates
      2017   -   NCT03644771   United States
   Icahn School of Medicine at Mount Sinai
      2018   Phase 4   NCT03025828   United States
   University of Colorado, Denver
      2019   Phase 3   NCT02683889   United States
   University of North Carolina, Chapel Hill
      2021   Phase 4   NCT02399462   United States
Acthar GEL
   Columbia University
      2009   Phase 4   NCT01129284   United States
   Mallinckrodt ARD LLC
      2016   Phase 4   NCT02633046   Argentina;Australia;Canada;Chile;Hong Kong;Mexico;New Zealand;Peru;Puerto Rico;Turkey;United States
Acthar GEL 80 UNT/ML injectable solution
   Rhode Island Hospital
      2018   Phase 4   NCT03408405   -
Acthar GEL and tacrolimus
   Southeast Renal Research Institute
      2012   -   NCT03042637   United States
Adalimumab
   New York University School of Medicine
      2008   Phase 2   NCT00814255   Canada;United States
   North Shore Long Island Jewish Health System
      2005   Phase 1   NCT00193648   United States
   University of Michigan
      2019   Phase 2   NCT04009668   United States
Adoport
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-003233-38-IT   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
Adrenocorticotrophic hormone
   Mao Jianhua
      2023   Phase 3   NCT06079788   China
Adrenocorticotrophic hormone acth
   University Health Network, Toronto
      2010   Phase 1/Phase 2   NCT01093157   Canada
Advagraf 0,5MG
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain
Advagraf 1MG
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain
Advagraf 5MG
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain
ADX-629
   Aldeyra Therapeutics, Inc.
      2023   Phase 2   NCT05599815   United States
AKF2328
   Radboudumc, Amalia Children’s Hospital, Department of Pediatrics
      2016   Phase 4   EUCTR2016-002430-76-NL   Belgium;Germany;Netherlands
Aldosterone
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 3   NCT01508468   France
   Chinese PLA General Hospital
      2023   Phase 4   NCT05839314   China
Alfacalcidol
   University of Aarhus
      2018   Phase 4   NCT03210688   Denmark
Aliskiren
   Columbia University
      2009   Phase 4   NCT01129557   United States
   Mayo Clinic
      2010   -   NCT01093781   United States
ALXN1920
   Alexion Pharmaceuticals, Inc.
      2025   Phase 2   NCT07157787   Argentina;Australia;Brazil;China;France;Italy;Spain;Taiwan;United Kingdom;United States
Ambrisentan
   The Second Affiliated Hospital of Army Medical University
      2025   -   ChiCTR2500108026   China
Amiloride
   Aarhus University Hospital
      2016   Phase 4   EUCTR2015-001946-26-DK   Denmark
   University Hospital Tuebingen
      2020   Phase 3   NCT05079789   Germany
      2020   Phase 3   EUCTR2019-002607-18-DE   Germany
Amlodipine
   Harada Ryoko
      2019   Phase 2   JPRN-jRCTs031180396   -
Angiotensin II
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 3   NCT01508468   France
ANTI-bcma/CD70 CAR-T cells
   The Children's Hospital of Zhejiang University School of Medicine
      2024   Phase 1   NCT06553898   China
ANTI-CD19 CAR-T cells
   The Children's Hospital of Zhejiang University School of Medicine
      2025   Phase 1   NCT06842589   China
ANTI-CD19/bcma CAR NK cells
   The Children's Hospital of Zhejiang University School of Medicine
      2025   Early Phase 1   NCT06792799   China
Anticorps monoclonaux
   CHU de LIMOGES
      2013   Phase 3   EUCTR2009-018266-35-BE   Belgium;France
      2010   Phase 3   EUCTR2009-018266-35-FR   Belgium;France
AP1189
   SynAct Pharma ApS
      2021   Phase 2   EUCTR2020-000971-18-NO   Denmark;Norway
      2020   Phase 2   EUCTR2020-000971-18-DK   Denmark;Norway
Apixaban
   Aarhus University Hospital, Henrik Birn
      2020   Phase 1;Phase 2   EUCTR2019-001212-29-DK   Denmark
   University of Aarhus
      2021   Phase 1/Phase 2   NCT04850378   Denmark
   University of North Carolina, Chapel Hill
      2017   Phase 1   NCT02599532   United States
Apixaban 5 MG
   University of North Carolina, Chapel Hill
      2021   Phase 1   NCT04278729   United States
APL-2
   Apellis Pharmaceuticals, Inc.
      2018   Phase 2   NCT03453619   United States
APL2
   Apellis Pharmaceuticals, Inc.
      2025   Phase 2/Phase 3   NCT07213960   United States
Aprovel 150 MG tablets
   Retrophin, Inc
      2015   Phase 2   EUCTR2014-002358-38-BE   Belgium;Czech Republic;Italy
      2014   Phase 2   EUCTR2014-002358-38-IT   Belgium;Czech Republic;Italy
   Travere Therapeutics, Inc.
      2015   Phase 2   EUCTR2014-002358-38-CZ   Belgium;Czech Republic;Czechia;Italy
Arzerra
   IRCCS Istituto Giannina Gaslini
      -   Phase 2   EUCTR2018-001042-33-IT   Italy
Arzerra - 100 MG - concentrato PER soluzione PER infusione - USO endovenoso - flacone(vetro) - 5 ML(20MG/ML) 3 flaconi
   IRCCS ISTITUTO GIANNINA GASLINI
      2015   Phase 2   EUCTR2015-000569-30-IT   Italy
      -   Phase 2   EUCTR2015-000624-28-IT   Italy
Atacicept
   Vera Therapeutics, Inc.
      2025   Phase 2   NCT06983028   United States
ATG
   Alice Bertaina
      2023   Phase 1/Phase 2   NCT05508009   United States
Atorvastatin
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1998   Phase 2   NCT00004466   United States
   National Institute of Kidney Disease and Urology (NIKDU)
      2024   Phase 4   NCT07497776   Bangladesh
Atrasentan
   CHINOOK THERAPEUTICS, U.S., Inc
      2021   Phase 2   EUCTR2020-004176-18-IT   Australia;Italy;Korea, Republic of;Spain;United Kingdom;United States
   Chinook Therapeutics U.S., Inc.
      2021   Phase 2   EUCTR2020-004176-18-ES   Australia;Korea, Republic of;Spain;United Kingdom;United States
Azithromycin
   Cairo University
      2018   -   JPRN-UMIN000035961   Africa
B007
   Shanghai Jiaolian Drug Research and Development Co., Ltd
      2024   Phase 2/Phase 3   NCT06470191   China
      2023   Phase 1   NCT05668403   China
Bardoxolone methyl capsules
   Biogen
      2017   Phase 2   NCT03366337   United States
Baseline glucocorticoid therapy
   Wuhan Children's Hospital
      2021   -   NCT07049172   China
Basiliximab
   Astellas Pharma Global Development, Inc.
      2017   Phase 2   NCT02921789   Canada;United States
BAT4406F
   Bio-Thera Solutions
      2025   Phase 2/Phase 3   NCT07499700   China
BCX9930
   BioCryst Pharmaceuticals
      2021   Phase 2   NCT05162066   France;Italy;Spain;United Kingdom
BCX9930 hydrochloride
   BIOCRYST PHARMACEUTICALS INC.
      2021   Phase 2   EUCTR2020-005855-19-IT   France;Germany;Hungary;Italy;Spain;United Kingdom
   BioCryst Pharmaceuticals Inc
      2022   Phase 2   EUCTR2020-005855-19-HU   France;Germany;Hungary;Italy;Romania;Spain;United Kingdom
      2021   Phase 2   EUCTR2020-005855-19-ES   France;Germany;Hungary;Italy;Spain;United Kingdom
Belimumab
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2012   -   EUCTR2011-000242-38-IT   Canada;Czech Republic;Germany;Italy;Spain;United Kingdom;United States
   GlaxoSmithKline Research & Development Ltd
      2013   -   EUCTR2011-000242-38-DE   Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2013   -   EUCTR2011-000242-38-CZ   Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2012   Phase 2   EUCTR2011-000242-38-GB   Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
   GlaxoSmithKline Research and Development Ltd
      2012   Phase 2   EUCTR2012-000385-38-GB   United Kingdom
   GlaxoSmithKline, S.A.
      2012   -   EUCTR2011-000242-38-ES   Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
   IRCCS Ospedale PedT..trico Bambino Gesù
      2018   Phase 2   EUCTR2017-003839-11-IT   Italy
   National Institute of Allergy and Infectious Diseases (NIAID)
      2020   Phase 2   NCT03949855   Canada;United States
   The Second Affiliated Hospital of Xi'an Jiaotong University
      2021   -   ChiCTR2100048518   China
Belimumab 10 MG
   GlaxoSmithKline
      2013   Phase 2   NCT01762852   Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
Benazepril
   The Second Affiliated Hospital of Army Medical University
      2025   -   ChiCTR2500108026   China
Benlysta
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2012   -   EUCTR2011-000242-38-IT   Canada;Czech Republic;Germany;Italy;Spain;United Kingdom;United States
   GlaxoSmithKline Research & Development Ltd
      2013   -   EUCTR2011-000242-38-DE   Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2013   -   EUCTR2011-000242-38-CZ   Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2012   Phase 2   EUCTR2011-000242-38-GB   Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
   GlaxoSmithKline Research and Development Ltd
      2012   Phase 2   EUCTR2012-000385-38-GB   United Kingdom
   GlaxoSmithKline, S.A.
      2012   -   EUCTR2011-000242-38-ES   Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
   IRCCS Ospedale PedT..trico Bambino Gesù
      2018   Phase 2   EUCTR2017-003839-11-IT   Italy
BI 764198
   Boehringer Ingelheim
      2026   Phase 3   NCT07220083   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Croatia;Denmark;Estonia;Finland;France;Georgia;Germany;Greece;Hong Kong;India;Italy;Japan;Malaysia;Mexico;Netherlands;New Zealand;Norway;Philippines;Poland;Portugal;Romania;Saudi Arabia;Singapore;Slovakia;South Korea;Spain;Sweden;Switzerland;Taiwan;Turkey (Türkiye);United Kingdom;United States
      2022   Phase 2   NCT05213624   Australia;Belgium;China;France;Germany;Ireland;Italy;New Zealand;Spain;United Kingdom;United States
   Boehringer Ingelheim España S.A.
      2022   Phase 2   EUCTR2020-000384-23-ES   Australia;Belgium;France;Germany;Hungary;Ireland;Italy;Spain;United Kingdom;United States
   Boehringer Ingelheim International GmbH
      2022   Phase 2   EUCTR2020-000384-23-IE   Australia;Belgium;China;France;Germany;Ireland;Italy;New Zealand;Spain;United Kingdom;United States
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2022   Phase 2   EUCTR2020-000384-23-DE   Australia;Belgium;China;France;Germany;Hungary;Ireland;Italy;Spain;United Kingdom;United States
   Boehringer Ingelheim SComm
      2022   Phase 2   EUCTR2020-000384-23-BE   Australia;Belgium;China;France;Germany;Ireland;Italy;New Zealand;Spain;United Kingdom;United States
   Boehringer-Ingelheim France
      2022   Phase 2   EUCTR2020-000384-23-FR   Australia;Belgium;France;Germany;Hungary;Ireland;Italy;Spain;United Kingdom;United States
Bleselumab
   Astellas Pharma Global Development, Inc.
      2017   Phase 2   NCT02921789   Canada;United States
Blinatumomab treatment
   The Children's Hospital of Zhejiang University School of Medicine
      2024   Phase 1   NCT06607991   China
Blood and urine analysis
   Centre Hospitalier Universitaire de Nice
      2015   -   NCT02199145   France
Blood sample
   Centre Hospitalier Universitaire de Nice
      2022   -   NCT05428605   France
      2020   -   NCT04326218   France
      2020   -   NCT04174066   France
Blood sampling
   Mario Negri Institute for Pharmacological Research
      2019   -   NCT05712369   Italy
   Yuebei People’s Hospital
      2022   Phase 0   ChiCTR2200058162   China
BMS-188667
   Bristol-Myers Squibb Company
      -   Phase 2   EUCTR2015-005450-36-Outside-EU/EEA   United States
Bortezomib
   Ruijin Hospital
      2022   -   NCT05383547   China
Brivekimig
   Sanofi
      2024   Phase 2   NCT06500702   Argentina;Australia;Brazil;Canada;Chile;China;Czechia;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Slovakia;Spain;Taiwan;Turkey (Türkiye);United Kingdom;United States
Budoprutug
   Climb Bio, Inc.
      2025   Phase 2   NCT07096843   Argentina;Brazil;Chile;China;Georgia;Taiwan;Ukraine;United States
Butyric acid
   Shanghai Children's Hospital
      2022   Phase 0   ChiCTR2200057174   China
C03db01
   Aarhus University Hospital
      2016   Phase 4   EUCTR2015-001946-26-DK   Denmark
Calcium
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 3   NCT01508468   France
   Guangzhou women and children's medical center
      2022   Phase 4   ChiCTR2200055790   China
Candesartan
   The Second Affiliated Hospital of Army Medical University
      2025   -   ChiCTR2500108026   China
CCX140-B
   Amgen
      2018   Phase 2   NCT03536754   Australia;Canada;France;Italy;New Zealand;Poland;United Kingdom;United States
   CHEMOCENTRYX, INC.
      2018   Phase 2   EUCTR2017-003021-15-IT   Australia;Canada;Czechia;France;Germany;Italy;New Zealand;Poland;United Kingdom;United States
   ChemoCentryx
      2018   Phase 2   NCT03703908   United States
   ChemoCentryx, Inc.
      2019   Phase 2   EUCTR2017-003022-32-PL   Canada;France;Poland;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003021-15-PL   Australia;Canada;Czech Republic;France;Germany;Italy;New Zealand;Poland;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003021-15-GB   Australia;Canada;Czech Republic;France;Germany;Italy;New Zealand;Poland;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003021-15-FR   Australia;Canada;Czech Republic;France;Germany;Italy;New Zealand;Poland;United Kingdom;United States
CD19 CAR-?D T cell
   Air Force Military Medical University, China
      2026   Early Phase 1   NCT07535138   China
CD19-targeted inkt cell injection
   Grit Biotechnology
      2026   Early Phase 1   NCT07389499   China
CD19/BCMA-targeted universal chimeric antigen receptor T cells (UCAR-T) infusing
   The First Affiliated Hospital of Zhejiang Chinese Medical University
      2026   Early Phase 1   NCT07423572   China
Cellcept
   F. Hoffman-La Roche Ltd
      2023   Phase 3   EUCTR2022-000369-42-PL   Belgium;Brazil;France;Germany;Italy;Poland;Spain;Turkey;United States
   F. Hoffman-La Roche Ltd.
      2023   Phase 3   EUCTR2022-000369-42-FR   Belgium;Brazil;France;Germany;Italy;Poland;Spain;Turkey;United States
      2023   Phase 3   EUCTR2022-000369-42-DE   Belgium;Brazil;France;Germany;Italy;Poland;Spain;Turkey;United States
   Imperial College Healthcare NHS trust
      2008   Phase 4   EUCTR2008-001009-41-GB   United Kingdom
   Kumamoto University, Department of Pediatrics
      2009   -   JPRN-UMIN000002740   Japan
   Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg and its Commercial
      2015   Phase 3   EUCTR2014-001991-76-DE   Germany
CF-CB-MSC
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
      2018   Phase 2   EUCTR2018-001162-42-IT   Italy
Cholecalciferol
   Hospices Civils de Lyon
      2014   Phase 4   NCT02238418   France
Cholesterol
   Yuebei People’s Hospital
      2022   Phase 0   ChiCTR2200058162   China
Ciclofosfamida
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain
Ciclosporin soft capsules
   Chinese PLA General Hospital
      2023   Phase 4   NCT05839314   China
Ciclosporina generis 100 MG Cápsulas moles
   AIBILI - Associação para Investigação Biomédica e Inovação em Luz e Imagem
      2013   -   EUCTR2013-001542-34-PT   Portugal
Clinimacs® TCR A/ß reagent KIT and clinimacs® CD19 system
   Alice Bertaina
      2023   Phase 1/Phase 2   NCT05508009   United States
Clopidogrel
   China-Japan Friendship Hospital Clinical Research Ethics Committee
      2018   -   ChiCTR1800015065   China
CO-intervention OF prednisolone wean during open label extension phase
   National University Hospital, Singapore
      2025   Phase 2   NCT07091175   Singapore
CO-intervention OF prednisolone wean during randomised controlled phase
   National University Hospital, Singapore
      2025   Phase 2   NCT07091175   Singapore
Conventional 24-week glucocorticoid regimen
   First Affiliated Hospital of Wenzhou Medical University
      2026   Phase 4   NCT07151456   China
   The First Affiliated Hospital of Wenzhou Medical University
      2026   Phase 4   ChiCTR2500111892   China
Conventional therapy
   China-Japan Friendship Hospital
      2021   Phase 4   ChiCTR2100050967   China
   Shanghai Children's Hospital
      2022   Phase 0   ChiCTR2200057174   China
   Toyama University Hospital
      2016   -   JPRN-UMIN000022422   Japan
   Zhujiang Hospital
      2016   Phase 2   NCT02966717   China
CORD-blood mesenchymal stromal cells
   Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
      2018   Phase 2   NCT04034316   Italy
Corticosteroid
   Children's Hospital of Fudan University
      2025   Phase 3   NCT05850546   China
   Children's Hospital,Zhejiang University School of Medicine
      2026   -   ChiCTR2600126859   China
   National Taiwan University Hospital
      2006   Phase 3   NCT00354731   Taiwan
   Shengjing Hospital of China Medical University
      2020   Phase 4   ChiCTR2300076346   China
Corticosteroids
   Tai'an Central Hospital
      2024   Phase 0   ChiCTR2400083681   China
   Tianjin Hospital
      2004   Phase 0   ChiCTR1900022518   China
   Wayne State University
      2019   Phase 4   NCT03878914   China;Egypt;India;Qatar;United States
Creatinine
   The Children's Hospital Zhejiang University School of Medicine
      2022   -   ChiCTR2300076574   China
   The Children's Hospital, Zhejiang University School of Medicine
      2022   -   ChiCTR2300076577   China
   Yuebei People’s Hospital
      2022   Phase 0   ChiCTR2200058162   China
CTX combined with glucocorticoids
   Huashan Hospital
      2024   Phase 3   NCT06781944   China
CXA-10
   Complexa, Inc.
      2018   Phase 2   NCT03422510   United States
Cyclophosphamide
   Asahi Kasei Pharma Corporation
      2014   Phase 3   NCT02257697   China
   Assistance Publique - Hôpitaux de Paris
      2010   Phase 3   NCT01092962   France
   Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
      2012   Phase 3   NCT03018535   Italy
   Baoji Central Hospital
      2016   -   ChiCTR-IPR-16008344   China
   Department of Nephrology, China-Japan Friendship Hospital
      2014   -   ChiCTR-IPR-14005366   -
   Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical University
      2019   -   ChiCTR1800019833   China
   Fundacion Renal Iñigo Alvarez Toledo
      2015   -   EUCTR2013-000226-55-NL   Netherlands;Spain
   Hospital Universitario 12 de Octubre
      2014   Phase 3   NCT01955187   Spain
   Nanjing University School of Medicine
      2011   -   NCT01451489   China
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 1/Phase 2   NCT00007475   United States
      1986   Phase 2   NCT00001212   United States
   Peking Union Medical College Hospital
      2021   Phase 3   NCT04745728   China
   Peking University Third Hospital
      2022   -   ChiCTR2200057381   China
   People’s Hospital of Guangxi Zhuang Autonomous Region
      2022   -   ChiCTR2200059658   China
   Renmin Hospital of Wuhan University
      2024   Phase 2   NCT06614985   China
   Ruijin Hospital, affiliated to Shanghai Jiaotong University, School of medicine
      2016   Phase 4   ChiCTR-IPR-16008527   China
   Shanghai Dongfang Hospital
      2021   Phase 0   ChiCTR2100049205   China
   Sichuan Provincial People's Hospital
      2018   -   ChiCTR1800016140   China
   The First Affiliated Hospital of Bengbu Medical College
      2020   Phase 4   ChiCTR2000033766   China
   The First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital
      2021   -   ChiCTR2100050205   China
   The Second Affiliated Hospital of Xi'an Jiaotong University
      2021   -   ChiCTR2100048518   China
   Tianjin First Central Hospital
      2017   -   ChiCTR-IPR-17011702   China
   West China Hospital, Sichuan University
      2025   -   ChiCTR2500103206   China
Cyclophosphamide 100 MG/KG
   Alice Bertaina
      2023   Phase 1/Phase 2   NCT05508009   United States
Cyclophosphamide 1200 MG/KG
   Alice Bertaina
      2023   Phase 1/Phase 2   NCT05508009   United States
Cyclophosphamide and steroids
   Radboud University
      1997   Phase 3   NCT00135954   Netherlands
Cyclosporin
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2004   Phase 3   NCT00135811   United States
   Sun Yat-sen University
      2014   Phase 2   NCT02173106   China
Cyclosporin A
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1986   Phase 2   NCT00001212   United States
Cyclosporin capsules
   Shanghai JMT-Bio Inc.
      2025   Phase 2   NCT07029139   -
   Shanghai Jiaolian Drug Research and Development Co., Ltd
      2024   Phase 2/Phase 3   NCT06470191   China
Cyclosporin, LOW dose steroid
   Kyungpook National University Hospital
      2011   Phase 3   NCT01282073   South Korea
Cyclosporine
   Beijing Hospital of TCM, Capital Medical University
      2023   Phase 2-3   ChiCTR2300067939   China
   Beijing Mabworks Biotech Co., Ltd.
      2023   Phase 3   NCT05862233   China
      2022   Phase 1/Phase 2   NCT05398653   China
   BioRay Pharmaceutical Co., Ltd.
      2024   Phase 2   NCT06642909   China
   First teaching hospital of Tianjin university of traditional chinese medicine
      2020   Phase 0   ChiCTR2200065012   China
   Japanese Study Group of Kidney Disease in Children
      2010   -   JPRN-UMIN000004204   Japan
      2005   -   JPRN-C000000008   Japan
      2005   -   JPRN-C000000007   Japan
   Japanese Study Group of Renal Disease in Children
      2001   -   JPRN-C000000009   Japan
      2000   -   JPRN-C000000010   Japan
      1996   -   JPRN-C000000014   Japan
   Mayo Clinic
      2011   Phase 2/Phase 3   NCT01180036   Canada;United States
   Nephrology Division, First Hospital Affiliated to Army Medical University
      2019   Phase 4   ChiCTR1900021757   China
   Peking Union Medical College Hospital
      2021   Phase 3   NCT04743739   China
   People’s Hospital of Guangxi Zhuang Autonomous Region
      2022   -   ChiCTR2200059658   China
   Renal Division, Peking University First Hospital
      2017   -   ChiCTR-INR-17012212   China
   Shanghai Children's Hospital
      2025   Phase 0   ChiCTR2500103238   China
   Tanaka Yu
      2020   Phase 2   JPRN-jRCTs051200070   -
   Yokohama city university graduate school of medicine
      2005   -   JPRN-UMIN000004653   Japan
   Yoshihiko Saito
      2007   -   JPRN-UMIN000000963   Japan
   Zhongshan Hospital, Fudan University
      2024   Phase 2   ChiCTR2400091563   China
Cyclosporine capsule
   Alexandria University
      2022   Phase 4   NCT05696977   Egypt
Cyclosporins
   Guangdong Provincial People's Hospital
      2018   Phase 4   NCT03170323   China
D-galactose
   Children's Research Institute
      2009   -   NCT01113385   United States
D5W
   Bristol-Myers Squibb
      2016   Phase 2   NCT02592798   United States
DacortíN 2,5MG
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain
DacortíN 30MG
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain
DacortíN 5MG
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain
Dalteparin
   Aarhus University Hospital, Henrik Birn
      2020   Phase 1;Phase 2   EUCTR2019-001212-29-DK   Denmark
   University of Aarhus
      2021   Phase 1/Phase 2   NCT04850378   Denmark
Dandshen
   First Affiliated Hospital of Wenzhou Medical University
      2012   -   NCT06071533   China
Danzhu fuyuan granule
   Jingqing Hu
      2020   -   NCT04498962   China
Dapagliflozin
   Ain Shams University
      2023   Phase 4   NCT05966818   -
   Mansoura University
      2025   Phase 2/Phase 3   NCT07214818   Egypt
   The First Affiliated Hospital of the People's Liberation Army Air Force University of Military Medicine
      2024   -   ChiCTR2400086359   China
   University Health Network, Toronto
      2015   Phase 4   NCT02585804   Canada
Dapagliflozin 10MG TAB
   Ain Shams University
      2022   Phase 4   NCT06026787   Egypt
Daratumumab
   Istituto Giannina Gaslini
      2023   Phase 2   NCT05704400   Italy
Depomedrol
   ISTITUTO GIANNINA GASLINI
      2008   -   EUCTR2007-007793-29-IT   Italy
Dexamethasone
   Ain Shams University
      2022   Phase 2/Phase 3   NCT05553496   -
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 2   NCT00004990   United States
Diphenhydramine
   Hoffmann-La Roche
      2021   Phase 3   NCT04629248   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russia;Spain;Turkey (Türkiye);Ukraine;United States
Diphenhydramine hydrochloride
   Hoffmann-La Roche
      2023   Phase 3   NCT05627557   Belgium;Brazil;China;France;Germany;Italy;Japan;Poland;Spain;Turkey (Türkiye);United States
Dipyridamole
   The Japanese Pediatric IgA Nephropathy of Treatment Study Group
      1998   -   JPRN-C000000375   Japan
DMX-200
   Dimerix Bioscience Pty Ltd
      2022   Phase 3   NCT05183646   Argentina;Australia;Brazil;China;Czechia;Denmark;France;Germany;Hong Kong;Italy;Japan;Malaysia;Mexico;New Zealand;Portugal;Spain;Taiwan;Thailand;Turkey (Türkiye);United Kingdom;United States
      2022   Phase 3   EUCTR2021-004174-64-FR   Argentina;Australia;Brazil;Denmark;France;Hong Kong;Korea, Republic of;New Zealand;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-004174-64-ES   Argentina;Australia;Brazil;Denmark;France;Hong Kong;Korea, Republic of;New Zealand;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-004174-64-DK   Argentina;Australia;Brazil;Denmark;France;Hong Kong;New Zealand;Spain;Taiwan;United Kingdom;United States
DNA chip dedicated TO THE pharmacogenetic OF steroids
   Assistance Publique - Hôpitaux de Paris
      2012   -   NCT01609426   France
Drug: atrasentan
   Novartis Pharmaceuticals
      2021   Phase 2   NCT04573920   Australia;Italy;South Korea;Spain;United Kingdom;United States
Dupilumab open label extension phase
   National University Hospital, Singapore
      2025   Phase 2   NCT07091175   Singapore
Edoxaban 60 MG
   Peking University People's Hospital
      2025   -   NCT07116239   -
Efgartigimod IV
   argenx
      2023   Phase 2   NCT05810961   China
Eliquis
   Aarhus University Hospital, Henrik Birn
      2020   Phase 1;Phase 2   EUCTR2019-001212-29-DK   Denmark
Elmisol
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 3   EUCTR2016-002324-92-FR   France
Empagliflozin
   Mansoura University
      2025   Phase 2/Phase 3   NCT07214818   Egypt
Enalapril
   The Second Affiliated Hospital of Army Medical University
      2025   -   ChiCTR2500108026   China
Endoxan baxter*50CPR RIV 50MG
   AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
      2012   -   EUCTR2011-006115-59-IT   Italy
Enoxaparin
   Military Institute of Medicine, Poland
      2015   Phase 2/Phase 3   NCT04558892   Poland
Enoxaparin 40 MG
   Peking University People's Hospital
      2025   -   NCT07116239   -
EVER001
   Everest Medicines (China) Co.,Ltd.
      2026   Phase 2   NCT07614477   China
      2023   Phase 1   NCT05800873   China
Evolocumab
   Department of Nephrology, Nippon Medical School
      2019   -   JPRN-UMIN000038242   Japan
   Department of Nephrology, Shandong Provincial Hospital affiliated to Shandong First Medical University
      2023   Phase 0   ChiCTR2300072268   China
Excreta
   Centre Hospitalier Universitaire de Nice
      2020   -   NCT04174066   France
Fecal microbiota
   Shanghai Children's Hospital
      2025   Phase 0   ChiCTR2500103238   China
   Zhang Ting
      2025   Early Phase 1   NCT07003438   -
Felzartamab
   Biogen
      2025   Phase 3   NCT06962800   Argentina;Australia;Brazil;Canada;China;India;Japan;Malaysia;South Korea;Taiwan;United States
   Matsuda Naoto
      2026   Phase 3   JPRN-jRCT2011250054   Japan;USA
   MorphoSys AG
      2021   Phase 1;Phase 2   EUCTR2019-000780-24-PL   Australia;Belgium;European Union;France;Italy;Korea, Republic of;Netherlands;Poland;Spain;United States
FG-3019
   FibroGen
      2008   Phase 1   NCT00782561   United States
Filgotinib
   Gilead Sciences
      2017   Phase 2   NCT03285711   United States
Finerenone
   General Hospital of Ningxia Medical University
      2025   -   ChiCTR2500103410   China
   The First Affiliated Hospital of the People's Liberation Army Air Force University of Military Medicine
      2024   -   ChiCTR2400086359   China
FK506
   Nanjing University School of Medicine
      2011   -   NCT01451489   China
   Shanghai Jiaotong University Affiliated Ruijin Hospital
      2008   -   ChiCTR-TRC-10001024   China
   Sun Yat-sen University
      2006   Phase 3   NCT00615667   -
   The Seventh Affiliated Hospital of Sun Yat sen University
      2023   Phase 4   ChiCTR2200067000   China
   Zhi-Hong Liu, M.D.
      2010   -   NCT01161459   China
FKC288
   Nanjing University School of Medicine
      2024   Phase 1   NCT06285279   China
Fludarabine
   Alice Bertaina
      2023   Phase 1/Phase 2   NCT05508009   United States
Fludarabine, cyclophosphamide
   Nkarta, Inc.
      2024   Phase 1/Phase 2   NCT06557265   Australia;Puerto Rico;United States
Fluvastatin
   Treatment center of kidney disease, 281th hospital of PLA
      2009   Phase 1 study   ChiCTR-TQR-12002602   China
Forxiga
   Centre Hospitalier Universitaire de Nice
      2025   Phase 2   NCT07096986   France
Fragmin
   Aarhus University Hospital, Henrik Birn
      2020   Phase 1;Phase 2   EUCTR2019-001212-29-DK   Denmark
Fresolimumab
   Genzyme Corporation
      2013   -   EUCTR2012-002365-35-IT   Brazil;France;Germany;Italy;Spain;United States
      2013   -   EUCTR2012-002365-35-ES   Brazil;France;Germany;Italy;Spain;United States
      2013   -   EUCTR2012-002365-35-DE   Brazil;France;Germany;Italy;Spain;United States
   Genzyme, a Sanofi Company
      2012   Phase 2   NCT01665391   Brazil;Germany;Italy;Spain;United States
Frexalimab
   Sanofi
      2024   Phase 2   NCT06500702   Argentina;Australia;Brazil;Canada;Chile;China;Czechia;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Slovakia;Spain;Taiwan;Turkey (Türkiye);United Kingdom;United States
Furosemid-ratiopharm® 40 MG
   University Hospital Tuebingen
      2020   Phase 3   EUCTR2019-002607-18-DE   Germany
Furosemid-ratiopharm® 40 mgtabletten
   University Hospital Tuebingen
      2020   Phase 3   EUCTR2019-002607-18-DE   Germany
Furosemide
   Khushnood Maqbool
      2026   -   ChiCTR2500113572   Pakistan
   University Hospital Tuebingen
      2020   Phase 3   NCT05079789   Germany
      2020   Phase 3   EUCTR2019-002607-18-DE   Germany
   the Affiliated Hospital of Guangdong Medical College
      2012   Phase 1 study   ChiCTR-TRC-12002146   China
   the Second Affiliated Hospital of Shantou University Medical College
      2019   Phase 4   ChiCTR1900022533   China
Furosemide and hydrochlorothiazide followed BY furosemide
   Shiraz University of Medical Sciences
      2015   Phase 4   NCT02427880   -
Furosemide injection
   Medical University of Bialystok
      2018   -   NCT03750136   Poland
Galactose
   New York University School of Medicine
      2008   Phase 2   NCT00814255   Canada;United States
   North Shore Long Island Jewish Health System
      2008   Phase 1   NCT00816504   United States
      2008   Phase 1   NCT00816478   United States
Gazyvaro
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-003233-38-IT   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
   F. Hoffman-La Roche Ltd
      2023   Phase 3   EUCTR2022-000369-42-PL   Belgium;Brazil;France;Germany;Italy;Poland;Spain;Turkey;United States
   F. Hoffman-La Roche Ltd.
      2023   Phase 3   EUCTR2022-000369-42-FR   Belgium;Brazil;France;Germany;Italy;Poland;Spain;Turkey;United States
      2023   Phase 3   EUCTR2022-000369-42-DE   Belgium;Brazil;France;Germany;Italy;Poland;Spain;Turkey;United States
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-003233-38-PL   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
      2021   Phase 3   EUCTR2020-003233-38-FR   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
Gazyvaro - 1000 MG - concentrato PER soluzione PER infusione - USO endovenoso - flaconcino - 1000MG/40ML - 1 flaconcino
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2021   Phase 2   EUCTR2021-004864-81-IT   Italy
Gazyvaro® 1000 MG/40 ML
   APHP
      2023   Phase 3   EUCTR2022-003336-59-FR   France
GC1008
   Genzyme Corporation
      2013   -   EUCTR2012-002365-35-IT   Brazil;France;Germany;Italy;Spain;United States
      2013   -   EUCTR2012-002365-35-ES   Brazil;France;Germany;Italy;Spain;United States
      2013   -   EUCTR2012-002365-35-DE   Brazil;France;Germany;Italy;Spain;United States
   Genzyme, a Sanofi Company
      2007   Phase 1   NCT00464321   Germany;Italy;United Kingdom;United States
Genotropin
   Pharmacia & Upjohn S.A.
      -   -   EUCTR2014-004104-30-Outside-EU/EEA   France
Genotyping OF THE NPHS2 variant RS61747728
   AHMED ABDULQADER HAMMOUDA ABOU SHALL
      2016   -   NCT03326037   Kuwait
Genoxal
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain
GFB-887
   Goldfinch Bio, Inc.
      2020   Phase 2   NCT04387448   United States
Glucocorticoid + cytoxan
   Qianfoshan Hospital
      2023   -   NCT05667883   -
Glucocorticoid + tacrolimus
   Qianfoshan Hospital
      2023   -   NCT05667896   -
Glucocorticoid combined with cyclophosphamide induction + maintenance
   RenJi Hospital
      2022   -   NCT05532111   -
   Renji Hospital Affiliated to Shanghai jiao tong university school of medicine
      2022   -   ChiCTR2200063389   China
GSK1550188
   GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
      2012   -   EUCTR2011-000242-38-IT   Canada;Czech Republic;Germany;Italy;Spain;United Kingdom;United States
   GlaxoSmithKline Research & Development Ltd
      2013   -   EUCTR2011-000242-38-DE   Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2013   -   EUCTR2011-000242-38-CZ   Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
      2012   Phase 2   EUCTR2011-000242-38-GB   Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
   GlaxoSmithKline Research and Development Ltd
      2012   Phase 2   EUCTR2012-000385-38-GB   United Kingdom
   GlaxoSmithKline, S.A.
      2012   -   EUCTR2011-000242-38-ES   Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States
GZ402669
   Genzyme Corporation
      2013   -   EUCTR2012-002365-35-IT   Brazil;France;Germany;Italy;Spain;United States
      2013   -   EUCTR2012-002365-35-ES   Brazil;France;Germany;Italy;Spain;United States
      2013   -   EUCTR2012-002365-35-DE   Brazil;France;Germany;Italy;Spain;United States
H.P. acthar GEL
   Stanford University
      2009   Phase 4   NCT01155141   United States
HS-10390 tablet
   Hansoh BioMedical R&D Company
      2023   Phase 1   NCT05942625   China
Huaier granule
   Chinese PLA General Hospital
      2023   Phase 4   NCT05839314   China
Huaiqihuang granule
   Jianhua Zhou
      2023   Phase 4   NCT05772871   China
Hydroxychloroquine
   Nephrology Division, First Hospital Affiliated to Army Medical University
      2019   Phase 4   ChiCTR1900021757   China
   Renal Division, Peking University First Hospital
      2016   -   ChiCTR2100045947   China
   Shengjing Hospital of China Medical University
      2020   Phase 4   ChiCTR2300076346   China
   The First Affiliated Hospital of the People's Liberation Army Air Force University of Military Medicine
      2024   -   ChiCTR2400086359   China
   The Seventh Affiliated Hospital of Sun Yat sen University
      2023   Phase 4   ChiCTR2200067000   China
Hypertonic saline
   Medical University of Bialystok
      2018   -   NCT03750136   Poland
IL-2 LOW dose
   University Hospital, Limoges
      2017   Phase 2   NCT02997150   France
Immunoglobulin IV
   Assistance Publique - Hôpitaux de Paris
      2019   Phase 2/Phase 3   NCT03560011   France
Immunoglobulines humaines normales
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2018   Phase 3   EUCTR2017-000826-36-FR   France
Indobufen
   China-Japan Friendship Hospital Clinical Research Ethics Committee
      2018   -   ChiCTR1800015065   China
   Zhejiang Provincial People's Hospital
      2017   Phase 4   ChiCTR-IPR-17013428   China
INN NOT available YET
   ChemoCentryx, Inc.
      2018   Phase 2   EUCTR2017-003021-15-PL   Australia;Canada;Czech Republic;France;Germany;Italy;New Zealand;Poland;United Kingdom;United States
Intravenous (I.V.) methylprednisolone 1000 MG, total 9
   Radboud University
      2002   Phase 2/Phase 3   NCT00135967   Netherlands
Intravenous injection
   Royan Institute
      2015   Phase 1   NCT02382874   Iran, Islamic Republic of
   Shanghai Children’s Hospital
      2025   Phase 0   ChiCTR2500101933   China
   Zhongshan Hospital, Fudan University
      2024   Phase 2   ChiCTR2400091563   China
Invirase
   OSPEDALE POLICLINICO S. MATTEO
      2009   -   EUCTR2009-013484-19-IT   Italy
Ioexolo
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2021   Phase 2   EUCTR2021-004864-81-IT   Italy
Iptacopan
   Novartis Pharma AG
      2020   Phase 2   EUCTR2019-001734-34-NL   Argentina;China;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-DE   Argentina;China;Czech Republic;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
Irbesartan
   Retrophin, Inc
      2015   Phase 2   EUCTR2014-002358-38-BE   Belgium;Czech Republic;Italy
      2014   Phase 2   EUCTR2014-002358-38-IT   Belgium;Czech Republic;Italy
   The Second Affiliated Hospital of Army Medical University
      2025   -   ChiCTR2500108026   China
   Travere Therapeutics, Inc.
      2018   Phase 3   NCT03493685   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;New Zealand;Poland;Portugal;South Korea;Spain;Sweden;Taiwan;United Kingdom;United States
      2015   Phase 2   EUCTR2014-002358-38-CZ   Belgium;Czech Republic;Czechia;Italy
      2014   Phase 2   NCT01613118   Belgium;Czechia;Italy;United States
Irbesartan tablets
   RETROPHIN, INC
      2018   Phase 3   EUCTR2016-005141-23-IT   Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Korea, Republic of;New Zealand;Poland;Portugal;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-005141-23-GB   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2016-005141-23-FR   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Italy;Korea, Republic of;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
Irbesartan tablets (approved IN THE USA. reference listed drug avapro) NDC # 43547-0374-03
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-005141-23-HU   Australia;Belgium;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Italy;Korea, Republic of;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2016-005141-23-ES   Australia;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Poland;South Africa;Spain;Taiwan;United Kingdom;United States
Irbesartan tablets (NDC# 43547-0374-03 and NDC 43547-374-09, approved IN THE USA) generic tablets distributed BY solco healthcare US, llcproduct name: OVER-encapsulated irbesartan tabletspharmaceutical form: capsule, hardinn or proposed INN: irbesartancas number: 138402-11-6other descriptive name: irbesartanconcentration unit: MG milligram(S)concentration type: equalconcentration number: 75-trade name: irbesartan tabletsproduct name: OVER-encapsulated irbesartan tabletspharmaceutical form: capsule, hardinn or proposed INN: irbesartancas number: 138402-11-6other descriptive name: irbesartanconcentration unit: MG milligram(S)concentration type: equalconcentration number: 75-product name: sparsentanproduct code: RE-021pharmaceutical form: tabletinn or proposed INN: sparsentancas number: 254740-64-2current sponsor code: RE-021other descriptive name: sparsentanconcentration unit: MG milligram(S)concentration type: equalconcentration number: 200-trade name: irbesartan tablets (NDC# 31722-729-30 approved IN THE united states)product name: OVER-encapsulated irbesartan tabletspharmaceutical form: capsule, hardcas number: 138402-11-6other descriptive name: irbesartanconcentration unit: MG milligram(S)concentration type: equalconcentration number: 75-product name: sparsentanproduct code: RE-021pharmaceutical form: tabletinn or proposed INN: sparsentancas number: 254740-64-2current sponsor code: RE-021O
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2016-005141-23-DE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
IXP
   Vertex Pharmaceuticals Incorporated
      2024   Phase 1   NCT06529796   United States
Jianpixiaozhong particles and wuse dietotherapy
   Shanghai University of Traditional Chinese Medicine
      2015   -   NCT02610595   China
JMT601 injection
   Shanghai JMT-Bio Inc.
      2025   Phase 2   NCT07029139   -
Ketosteril
   Military Institute of Medicine, Poland
      2023   Phase 3   NCT05716880   Poland
Kidney transplant
   Alice Bertaina
      2023   Phase 1/Phase 2   NCT05508009   United States
Lanraplenib
   Gilead Sciences
      2017   Phase 2   NCT03285711   United States
Lansoprazole, amoxicillin, clarithromycin
   Istanbul University
      2006   -   NCT00983034   Turkey
Levamidole 50MG
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 3   EUCTR2016-002324-92-FR   France
Levamisole
   Henan Children's HospitalChildren's Hospital of Zhengzhou UniversityHenan Children's Hospital Zhengzhou Children's Hospital
      2023   Phase 0   ChiCTR2400091896   China
   Jianhua Zhou
      2023   Phase 4   NCT05772871   China
Levamisole 10 MG
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2009   -   EUCTR2005-005745-18-FR   Belgium;France
   Academic Medical Center
      2018   Phase 3   EUCTR2017-001025-41-NL   Belgium;Netherlands
   Amsterdam University Medical Center, location AMC
      2019   Phase 3   EUCTR2017-001025-41-BE   Belgium;Netherlands
Levamisole 10MG
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 3   EUCTR2016-002324-92-FR   France
Levamisole 25 MG
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2009   -   EUCTR2005-005745-18-FR   Belgium;France
   Academic Medical Center
      2018   Phase 3   EUCTR2017-001025-41-NL   Belgium;Netherlands
   Amsterdam University Medical Center, location AMC
      2019   Phase 3   EUCTR2017-001025-41-BE   Belgium;Netherlands
Levamisole 25MG
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 3   EUCTR2016-002324-92-FR   France
Levamisole 5 MG
   Academic Medical Center
      2018   Phase 3   EUCTR2017-001025-41-NL   Belgium;Netherlands
   Amsterdam University Medical Center, location AMC
      2019   Phase 3   EUCTR2017-001025-41-BE   Belgium;Netherlands
Levamisole 50 MG
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2009   -   EUCTR2005-005745-18-FR   Belgium;France
   Academic Medical Center
      2018   Phase 3   EUCTR2017-001025-41-NL   Belgium;Netherlands
   Amsterdam University Medical Center, location AMC
      2019   Phase 3   EUCTR2017-001025-41-BE   Belgium;Netherlands
Levamisole 5MG
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2009   -   EUCTR2005-005745-18-FR   Belgium;France
      -   Phase 3   EUCTR2016-002324-92-FR   France
Levamisole chlorhydrate
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2009   -   EUCTR2005-005745-18-FR   Belgium;France
Levamisole hydrochloride
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 3   EUCTR2016-002324-92-FR   France
   Academic Medical Center
      2018   Phase 3   EUCTR2017-001025-41-NL   Belgium;Netherlands
   Amsterdam University Medical Center, location AMC
      2019   Phase 3   EUCTR2017-001025-41-BE   Belgium;Netherlands
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 3   NCT02818738   France
   Emma Children's Hospital-AMC
      2007   Phase 3   EUCTR2005-005745-18-BE   Belgium;France
Lisinopril, losartan, and atorvastatin
   New York University School of Medicine
      2008   Phase 2   NCT00814255   Canada;United States
LNP023
   Novartis Farmacéutica, S.A.
      2019   Phase 2   EUCTR2019-001734-34-ES   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States
   Novartis Pharma AG
      2020   Phase 2   EUCTR2019-001734-34-NL   Argentina;China;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-GB   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-FR   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-DE   Argentina;China;Czech Republic;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
   Novartis Pharmaceuticals
      2019   Phase 2   NCT04154787   Argentina;China;Czechia;France;Germany;India;Netherlands;Singapore;Spain;Taiwan;United Kingdom;United States
Long term tapering OF prednisolone
   Institute of Child Health
      2003   Phase 4   NCT00308321   United Kingdom
Losartan
   Shanghai University of T.C.M
      2014   -   ChiCTR-TRC-14005064   China
   The Second Affiliated Hospital of Army Medical University
      2025   -   ChiCTR2500108026   China
Losartan tablets & qingremoshen granule
   wanglin
      2011   -   NCT01845688   China
Losmapimod
   GlaxoSmithKline
      2014   Phase 2   NCT02000440   Canada;United States
Mabthera
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
      2019   Phase 2   EUCTR2018-003437-15-FR   France
   Fundacion Renal Iñigo Alvarez Toledo
      2015   -   EUCTR2013-000226-55-NL   Netherlands;Spain
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2009   Phase 3   EUCTR2008-006750-17-IT   Italy
   ISTITUTO GIANNINA GASLINI
      2008   -   EUCTR2008-004486-26-IT   Italy
Mabthera - 1 fiala 500 MG 50 ML
   IRCCS ISTITUTO GIANNINA GASLINI
      -   Phase 2   EUCTR2015-000624-28-IT   Italy
Mabthera 100 MG concentrate FOR solution FOR infusion
   Novartis Pharma AG
      2020   Phase 2   EUCTR2019-001734-34-NL   Argentina;China;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-GB   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-FR   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-DE   Argentina;China;Czech Republic;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
Mabthera 100MG
   CHU de LIMOGES
      2013   Phase 3   EUCTR2009-018266-35-BE   Belgium;France
Mabthera 100MG concentrate FOR solution FOR infusion
   MEDICAL UNIVERSITY OF GDANSK
      2021   Phase 3   EUCTR2020-004982-37-PL   Poland
Mabthera 100MG, concentrate FOR solution FOR infusion
   MEDICAL UNIVERSITY OF GDANSK
      2021   Phase 3   EUCTR2020-004982-37-PL   Poland
Mabthera 500 MG concentrate FOR solution FOR infusion
   Novartis Pharma AG
      2020   Phase 2   EUCTR2019-001734-34-NL   Argentina;China;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-GB   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-DE   Argentina;China;Czech Republic;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
Mabthera 500MG
   CHU de LIMOGES
      2013   Phase 3   EUCTR2009-018266-35-BE   Belgium;France
Mabthera*EV 1FL 50ML 500MG
   AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
      2012   -   EUCTR2011-006115-59-IT   Italy
MabthéRA 100MG
   CHU de LIMOGES
      2010   Phase 3   EUCTR2009-018266-35-FR   Belgium;France
MabthéRA 500MG
   CHU de LIMOGES
      2010   Phase 3   EUCTR2009-018266-35-FR   Belgium;France
Mannac
   National Human Genome Research Institute (NHGRI)
      2026   Phase 2   NCT06664814   United States
Medrol
   Hopital Erasme
      2006   Phase 4   EUCTR2005-004460-22-BE   Belgium
Medrol*10CPR DIV 4MG
   AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
      2012   -   EUCTR2011-006115-59-IT   Italy
Melphalan
   Alice Bertaina
      2023   Phase 1/Phase 2   NCT05508009   United States
Mesenchymal stem cells
   Zhujiang Hospital
      2016   Phase 2   NCT02966717   China
Metformin + standard OF care
   Yale University
      2023   Phase 1/Phase 2   NCT06090227   United States
Methylprednisolone
   Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
      2012   Phase 3   NCT03018535   Italy
   Fundacion Renal Iñigo Alvarez Toledo
      2015   -   EUCTR2013-000226-55-NL   Netherlands;Spain
   Hoffmann-La Roche
      2023   Phase 3   NCT05627557   Belgium;Brazil;China;France;Germany;Italy;Japan;Poland;Spain;Turkey (Türkiye);United States
      2021   Phase 3   NCT04629248   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russia;Spain;Turkey (Türkiye);Ukraine;United States
   Hospital Universitario 12 de Octubre
      2014   Phase 3   NCT01955187   Spain
   ISTITUTO GIANNINA GASLINI
      2008   -   EUCTR2007-007793-29-IT   Italy
   Japanese Study Group of Kidney Disease in Children
      2015   -   JPRN-UMIN000014895   Japan
      2005   -   JPRN-C000000007   Japan
   Japanese Study Group of Renal Disease in Children
      2001   -   JPRN-C000000009   Japan
   The First Affiliated Hospital of Dalian Medical University
      2009   -   ChiCTR-ONC-12002809   China
   Tianjin Hospital
      2004   Phase 0   ChiCTR1900022518   China
Methylprednisolone sodium succinate
   Nozu Kandai
      2019   Phase 3   JPRN-jRCT2051190019   -
Methylprednisone
   Astellas Pharma Global Development, Inc.
      2017   Phase 2   NCT02921789   Canada;United States
Metolazone
   Khushnood Maqbool
      2026   -   ChiCTR2500113572   Pakistan
MIL62
   Beijing Mabworks Biotech Co., Ltd.
      2023   Phase 3   NCT05862233   China
      2022   Phase 1/Phase 2   NCT05398653   China
Mizoribine
   Asahi Kasei Pharma Corporation
      2014   Phase 3   NCT02257697   China
   Japanese Study Group of Kidney Disease in Children
      2011   -   JPRN-UMIN000005103   Japan
   Japanese Study Group of Renal Disease in Children(JSRDC)
      2006   -   JPRN-C000000158   Japan
      2001   -   JPRN-C000000379   Japan
   Nakanishi Koichi
      2011   Phase 3   JPRN-jRCTs071180060   -
   Project team for treatment of refractory nephrotic syndrome
      2004   -   JPRN-C000000368   Japan
   Tanaka Yu
      2020   Phase 2   JPRN-jRCTs051200070   -
   The Japanese Pediatric IgA Nephropathy of Treatment Study Group
      1998   -   JPRN-C000000375   Japan
   The study group of treatment for aged patients with nephrotic syndrome.
      2012   -   JPRN-UMIN000008919   Japan
   Tianjin First Central Hospital
      2017   -   ChiCTR-IPR-17011702   China
MMF
   Astellas Pharma Global Development, Inc.
      2017   Phase 2   NCT02921789   Canada;United States
   Hoffmann-La Roche
      2023   Phase 3   NCT05627557   Belgium;Brazil;China;France;Germany;Italy;Japan;Poland;Spain;Turkey (Türkiye);United States
   Nationwide Children's Hospital
      2015   Phase 3   NCT02390362   United States
   Will Pendergraft, M.D., Ph.D.
      2023   Phase 3   JPRN-jRCT2011220036   Belgium;Brazil;China;France;Germany;Italy;Japan;Poland;Spain;Turkey;United States
MMF and dexamethasone
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2004   Phase 3   NCT00135811   United States
Modamide 5 MG tablet
   University Hospital Tuebingen
      2020   Phase 3   EUCTR2019-002607-18-DE   Germany
Modified ponticelli regimen
   Beijing Friendship Hospital
      2022   -   NCT05782933   China
Montelukast
   Nishtar Medical University
      2019   -   NCT04818723   Pakistan
MOR03087
   Human Immunology Biosciences, Inc.
      2020   Phase 2   EUCTR2020-002985-15-GR   Georgia;Germany;Greece;Korea, Republic of;Russian Federation;United Kingdom
   MorphoSys AG
      2021   Phase 1;Phase 2   EUCTR2019-000780-24-PL   Australia;Belgium;European Union;France;Italy;Korea, Republic of;Netherlands;Poland;Spain;United States
      2020   Phase 2   EUCTR2020-002985-15-GB   Australia;Georgia;Germany;Greece;Korea, Republic of;Russian Federation;Taiwan;United Kingdom
      2020   Phase 2   EUCTR2020-002985-15-DE   France;Georgia;Germany;Greece;Hong Kong;Korea, Republic of;Russian Federation;Taiwan;United Kingdom
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-NL   Australia;European Union;France;Italy;Korea, Republic of;Netherlands;Poland;Spain;United States
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-IT   Belgium;European Union;France;Italy;Netherlands;Poland;Spain;United States
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-FR   Belgium;European Union;France;Italy;Netherlands;Poland;Spain;United States
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-ES   Belgium;European Union;France;Italy;Netherlands;Poland;Spain;United States
MOR202
   HI-Bio, A Biogen Company
      2021   Phase 2   NCT04733040   Georgia;Germany;Greece;Korea, Republic of;Russian Federation;Taiwan;United Kingdom
      2019   Phase 1/Phase 2   NCT04145440   Australia;Belgium;France;Italy;Korea, Republic of;Netherlands;Poland;Spain;United States
   Human Immunology Biosciences, Inc.
      2020   Phase 2   EUCTR2020-002985-15-GR   Georgia;Germany;Greece;Korea, Republic of;Russian Federation;United Kingdom
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2021   Phase 2   EUCTR2021-000835-30-IT   Italy
   Mario Negri Institute for Pharmacological Research
      2021   Phase 2   NCT04893096   Italy
   MorphoSys AG
      2021   Phase 1;Phase 2   EUCTR2019-000780-24-PL   Australia;Belgium;European Union;France;Italy;Korea, Republic of;Netherlands;Poland;Spain;United States
      2020   Phase 2   EUCTR2020-002985-15-GB   Australia;Georgia;Germany;Greece;Korea, Republic of;Russian Federation;Taiwan;United Kingdom
      2020   Phase 2   EUCTR2020-002985-15-DE   France;Georgia;Germany;Greece;Hong Kong;Korea, Republic of;Russian Federation;Taiwan;United Kingdom
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-NL   Australia;European Union;France;Italy;Korea, Republic of;Netherlands;Poland;Spain;United States
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-IT   Belgium;European Union;France;Italy;Netherlands;Poland;Spain;United States
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-FR   Belgium;European Union;France;Italy;Netherlands;Poland;Spain;United States
      2019   Phase 1;Phase 2   EUCTR2019-000780-24-ES   Belgium;European Union;France;Italy;Netherlands;Poland;Spain;United States
MP and CTX
   Wenhu Liu
      2018   -   NCT03466801   China
Multi-omics analysis
   Mario Negri Institute for Pharmacological Research
      2026   -   NCT07416942   Italy
Mycophenolate mofetil
   Assistance Publique - Hôpitaux de Paris
      2010   Phase 3   NCT01092962   France
   Astellas Pharma Global Development, Inc.
      2017   Phase 2   NCT02921789   Canada;United States
   Children's Hospital of Chongqing Medical University
      2023   Phase 2   NCT05843968   China
   Children's Hospital of Fudan University
      2020   Phase 3   NCT04531865   China
   Department of Pediatrics, Faculty of Life Sciences, Kumamoto University
      2012   -   JPRN-UMIN000015052   Japan
      2012   -   JPRN-UMIN000015051   Japan
   F. Hoffman-La Roche Ltd
      2023   Phase 3   EUCTR2022-000369-42-PL   Belgium;Brazil;France;Germany;Italy;Poland;Spain;Turkey;United States
   F. Hoffman-La Roche Ltd.
      2023   Phase 3   EUCTR2022-000369-42-FR   Belgium;Brazil;France;Germany;Italy;Poland;Spain;Turkey;United States
      2023   Phase 3   EUCTR2022-000369-42-DE   Belgium;Brazil;France;Germany;Italy;Poland;Spain;Turkey;United States
   Guangdong Provincial People's Hospital
      2018   Phase 4   NCT03170323   China
   Huashan Hospital, Fudan University
      2026   Phase 4   ChiCTR2600125299   China
   IRCCS Istituto Giannina Gaslini
      -   Phase 2   EUCTR2018-001042-33-IT   Italy
   Istituto Giannina Gaslini
      2019   Phase 2   NCT04402580   Italy
   Japanese Study Group of Kidney Disease in Children
      2015   Phase 3   JPRN-UMIN000014347   Japan
   Kumamoto University, Department of Pediatrics
      2009   -   JPRN-UMIN000002740   Japan
   Kumamoto University, Faculty of Life Sciences, Department of Pediatrics
      2012   -   JPRN-UMIN000007511   Japan
   Nilratan Sircar Medical College
      2019   Phase 3   NCT03899103   India
   Nozu Kandai
      2015   Phase 3   JPRN-jRCTs051180081   -
   Radboud University
      2002   Phase 2/Phase 3   NCT00135967   Netherlands
   Seoul National University Hospital
      2013   Phase 4   NCT01895894   Korea, Republic of
   The Children's Hospital of Zhejiang University School of Medicine
      2019   Phase 4   NCT04048161   China
   The First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital
      2021   -   ChiCTR2100050205   China
   Will Pendergraft, M.D., Ph.D.
      2023   Phase 3   JPRN-jRCT2011220036   Belgium;Brazil;China;France;Germany;Italy;Japan;Poland;Spain;Turkey;United States
Mycophenolate mofetil, LOW dose steroid
   Kyungpook National University Hospital
      2011   Phase 3   NCT01282073   South Korea
Mycophenolate sodium
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Mycophenolatmofetile
   Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg and its Commercial
      2015   Phase 3   EUCTR2014-001991-76-DE   Germany
Mycophenolic acid
   Children's Hospital, Zhejiang University School of Medicine
      2019   Phase 4   ChiCTR1900025533   China
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Mycophenolic sodium
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Mycophenylate mofetil
   Imperial College Healthcare NHS trust
      2008   Phase 4   EUCTR2008-001009-41-GB   United Kingdom
Mycopheylate mofetil
   Imperial College Healthcare NHS trust
      2008   Phase 4   EUCTR2008-001009-41-GB   United Kingdom
Myfenax
   IRCCS Istituto Giannina Gaslini
      -   Phase 2   EUCTR2018-001042-33-IT   Italy
Myfortic
   Assistance Publique - Hôpitaux de Paris
      2009   Phase 3   NCT01197040   France
Myfortic 180MG tablets
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Myfortic 360MG tablets
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
Myfortic plus LOW-dose steroid
   The University of Hong Kong
      2010   Phase 4   NCT01185197   China
Narsoplimab
   Omeros Corporation
      2016   Phase 2   NCT02682407   Hong Kong;United States
Neoral
   Hopital Erasme
      2006   Phase 4   EUCTR2005-004469-40-BE   Belgium
      2006   Phase 4   EUCTR2005-004460-22-BE   Belgium
   Kyoto university hospital
      2010   Phase 4   JPRN-UMIN000003245   Japan
NKX019
   Nkarta, Inc.
      2024   Phase 1/Phase 2   NCT06557265   Australia;Puerto Rico;United States
None YET
   Boehringer Ingelheim España S.A.
      2022   Phase 2   EUCTR2020-000384-23-ES   Australia;Belgium;France;Germany;Hungary;Ireland;Italy;Spain;United Kingdom;United States
   Boehringer Ingelheim International GmbH
      2022   Phase 2   EUCTR2020-000384-23-IE   Australia;Belgium;China;France;Germany;Ireland;Italy;New Zealand;Spain;United Kingdom;United States
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2022   Phase 2   EUCTR2020-000384-23-DE   Australia;Belgium;China;France;Germany;Hungary;Ireland;Italy;Spain;United Kingdom;United States
   Boehringer Ingelheim SComm
      2022   Phase 2   EUCTR2020-000384-23-BE   Australia;Belgium;China;France;Germany;Ireland;Italy;New Zealand;Spain;United Kingdom;United States
   Boehringer-Ingelheim France
      2022   Phase 2   EUCTR2020-000384-23-FR   Australia;Belgium;France;Germany;Hungary;Ireland;Italy;Spain;United Kingdom;United States
Normal saline
   Bristol-Myers Squibb
      2016   Phase 2   NCT02592798   United States
Obinutuzumab
   F. Hoffman-La Roche Ltd
      2023   Phase 3   EUCTR2022-000369-42-PL   Belgium;Brazil;France;Germany;Italy;Poland;Spain;Turkey;United States
   F. Hoffman-La Roche Ltd.
      2023   Phase 3   EUCTR2022-000369-42-FR   Belgium;Brazil;France;Germany;Italy;Poland;Spain;Turkey;United States
      2023   Phase 3   EUCTR2022-000369-42-DE   Belgium;Brazil;France;Germany;Italy;Poland;Spain;Turkey;United States
   Hoffmann-La Roche
      2023   Phase 3   NCT05627557   Belgium;Brazil;China;France;Germany;Italy;Japan;Poland;Spain;Turkey (Türkiye);United States
      2021   Phase 3   NCT04629248   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russia;Spain;Turkey (Türkiye);Ukraine;United States
   Huashan Hospital
      2024   Phase 3   NCT06781944   China
   Mario Negri Institute for Pharmacological Research
      2026   Phase 2   NCT07233330   Italy
      2022   Phase 2   NCT05050214   Italy
   Mayo Clinic
      2021   Phase 2   NCT04983888   United States
   The Second Hospital of Shanxi Medical University
      2024   -   ChiCTR2400082133   China
   The Second People's Hospital of Shenzhen
      2024   -   ChiCTR2400083188   China
   The University of Queensland
      2025   Phase 3   NCT06120673   Australia
   Will Pendergraft, M.D., Ph.D.
      2023   Phase 3   JPRN-jRCT2011220036   Belgium;Brazil;China;France;Germany;Italy;Japan;Poland;Spain;Turkey;United States
Obinutuzumab administration
   Radboud University Medical Center
      2025   Phase 2/Phase 3   NCT07163611   Netherlands
Obinutuzumab injection
   Qianfoshan Hospital
      2023   -   NCT05845762   -
Obinutuzumab/ GA101
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-003233-38-IT   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-003233-38-PL   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
      2021   Phase 3   EUCTR2020-003233-38-FR   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
Obitunuzumab
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2021   Phase 2   EUCTR2021-004864-81-IT   Italy
Observation OF THE adverse outcomes OF cyclosporine IN steroid dependent and frequent relapsing nephrotic syndrome IN children
   Sohag University
      2022   -   NCT05588869   Egypt
Ofatumumab
   IRCCS ISTITUTO GIANNINA GASLINI
      2015   Phase 2   EUCTR2015-000569-30-IT   Italy
      -   Phase 2   EUCTR2015-000624-28-IT   Italy
   IRCCS Istituto Giannina Gaslini
      -   Phase 2   EUCTR2018-001042-33-IT   Italy
   Istituto Giannina Gaslini
      2015   Phase 2   NCT02394119   Italy
      2015   Phase 2   NCT02394106   Italy
Omnipaque
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2021   Phase 2   EUCTR2021-004864-81-IT   Italy
OMS721
   Omeros Corporation
      2016   Phase 2   NCT02682407   Hong Kong;United States
Oral cyclosporine
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2010   Phase 2   NCT00977977   United States
Oral prednisolone and cyclophosphamide
   The University of Queensland
      2025   Phase 3   NCT06120673   Australia
Orencia
   Bristol-Myers Squibb Company
      -   Phase 2   EUCTR2015-005450-36-Outside-EU/EEA   United States
OVER-encapsulated 75 MG irbesartan tablets
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-005141-23-HU   Australia;Belgium;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Italy;Korea, Republic of;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2016-005141-23-ES   Australia;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Poland;South Africa;Spain;Taiwan;United Kingdom;United States
OVER-encapsulated irbesartan
   RETROPHIN, INC
      2018   Phase 3   EUCTR2016-005141-23-IT   Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Korea, Republic of;New Zealand;Poland;Portugal;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2016-005141-23-SE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2016-005141-23-PT   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2016-005141-23-BE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2016-005141-23-DK   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2016-005141-23-CZ   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
OVER-encapsulated irbesartan tablets
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2016-005141-23-HR   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2016-005141-23-EE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
   Travere Therapeutics, Inc.
      2018   Phase 3   EUCTR2016-005141-23-PL   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
Peginterferon ALFA-2A 180 MCG/ML injectable solution
   Centre Hospitalier Universitaire de Nice
      2023   Phase 2   NCT05941845   France
Pentoxifylline
   National Taiwan University Hospital
      2006   Phase 3   NCT00354731   Taiwan
Perindopril
   Nephrology Division, First Hospital Affiliated to Army Medical University
      2019   Phase 4   ChiCTR1900021757   China
PF-06730512
   PFIZER INC
      2020   Phase 2   EUCTR2019-003607-35-IT   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Poland;Romania;Slovakia;Spain;United Kingdom;United States
   Pfizer
      2018   Phase 2   NCT03448692   Canada;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Slovakia;Spain;United Kingdom;United States
   Pfizer Inc.
      2020   Phase 2   EUCTR2019-003607-35-SK   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Slovakia;Spain;Thailand;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003607-35-PL   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Slovakia;Spain;Thailand;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003607-35-DE   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Slovakia;Spain;Thailand;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003607-35-CZ   Canada;Czech Republic;Czechia;France;Germany;Italy;Japan;Poland;Romania;Slovakia;Spain;Thailand;United Kingdom;United States
Pirfenidone
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1999   Phase 2   NCT00001959   United States
Plasma exchange
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 1/Phase 2   NCT00007475   United States
Plasmapheresis
   University of Minnesota
      2019   Early Phase 1   NCT03763643   United States
Ponticelli regimen
   Beijing Friendship Hospital
      2020   Phase 4   NCT04424862   China
Povetacicept
   Alpine Immune Sciences, Inc.
      2023   Phase 1/Phase 2   NCT05732402   Australia;Austria;Norway;Puerto Rico;South Korea;Spain;United Kingdom;United States
   Vertex Pharmaceuticals Incorporated
      2025   Phase 2/Phase 3   NCT07204275   Australia;Brazil;China;Czechia;Germany;Hungary;Ireland;Italy;Japan;South Korea;Spain;United Kingdom;United States
Praliciguat
   Akebia Therapeutics
      2025   Phase 2   NCT07268638   United States
Pravastatin
   University of North Carolina, Chapel Hill
      2012   Phase 1   NCT01845428   United States
Prednisolon 5 MG, tabletten
   Radboudumc, Amalia Children’s Hospital, Department of Pediatrics
      -   Phase 4   EUCTR2016-002430-76-BE   Belgium;Germany;Netherlands
Prednisolon mylan 20 MG
   Radboudumc, Amalia Children’s Hospital, Department of Pediatrics
      -   Phase 4   EUCTR2016-002430-76-BE   Belgium;Germany;Netherlands
Prednisolone
   All India Institute of Medical Sciences, New Delhi
      2015   Phase 3   NCT03141970   India;United States
   Astellas Pharma Korea, Inc.
      2012   Phase 4   NCT01763580   Korea, Republic of
      -   -   EUCTR2015-001039-18-Outside-EU/EEA   Korea, Republic of
   Children's Hospital Affiliated to Fudan UniversityNanjing Children's Hospital
      2010   -   ChiCTR-TRC-10000871   China
   Children's Hospital of Fudan University
      2020   Phase 3   NCT04536181   China
      2020   Phase 4   ChiCTR2000037663   China
   Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan
      2007   -   JPRN-UMIN000000621   Japan
   Imperial College NHS trust
      2009   Phase 4   EUCTR2009-014292-52-GB   United Kingdom
   Japanese Study Group of Kidney Disease in Children
      2011   -   JPRN-UMIN000005103   Japan
      2005   -   JPRN-C000000007   Japan
   Japanese Study Group of Renal Disease in Children
      2001   -   JPRN-C000000009   Japan
   Japanese Study Group of Renal Disease in Children(JSRDC)
      2006   -   JPRN-C000000158   Japan
      2001   -   JPRN-C000000379   Japan
   Kyoto university hospital
      2010   Phase 4   JPRN-UMIN000003245   Japan
   Nakanishi Koichi
      2011   Phase 3   JPRN-jRCTs071180060   -
   Radboudumc, Amalia Children’s Hospital, Department of Pediatrics
      -   Phase 4   EUCTR2016-002430-76-BE   Belgium;Germany;Netherlands
   Shaheed Zulfiqar Ali Bhutto Medical University
      2020   -   NCT04713410   Pakistan
   Shanghai Jiaotong University Affiliated Ruijin Hospital
      2008   -   ChiCTR-TRC-10001024   China
   The Children's Hospital Zhejiang University School of Medicine
      2022   -   ChiCTR2300076574   China
   The First Affiliated Hospital of Wenzhou Medical University
      2026   Phase 4   ChiCTR2500111892   China
   The Japanese Pediatric IgA Nephropathy of Treatment Study Group
      1998   -   JPRN-C000000375   Japan
   The University of Birmingham
      2012   Phase 3   EUCTR2012-003476-39-GB   United Kingdom
      2011   Phase 3   EUCTR2010-022489-29-GB   United Kingdom
   The University of Hong Kong
      2010   Phase 4   NCT01185197   China
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom
   University of Aarhus
      2018   Phase 4   NCT03210688   Denmark
   Yamamura Tomohiko
      2024   Phase 3   JPRN-jRCT2051240106   -
Prednisolone acetate
   Fundacion Renal Iñigo Alvarez Toledo
      2015   -   EUCTR2013-000226-55-NL   Netherlands;Spain
   Radboud University Nijmegen Medical Center
      2017   Phase 3   EUCTR2017-003366-27-NL   Netherlands
   Radboudumc, Amalia Children’s Hospital, Department of Pediatrics
      2019   Phase 3   EUCTR2016-002430-76-DE   Belgium;Germany;Netherlands
Prednisolone and chlorambucil
   Hospital Authority, Hong Kong
      2003   Phase 3   NCT00404833   China
Prednisolone and mycophenolate mofetil
   Hospital Authority, Hong Kong
      2003   Phase 3   NCT00404833   China
Prednisolone solution 5MG/ML
   Radboudumc, Amalia Children’s Hospital, Department of Pediatrics
      2016   Phase 4   EUCTR2016-002430-76-NL   Belgium;Germany;Netherlands
Prednisona
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain
Prednisone
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
      2019   Phase 2   EUCTR2018-003437-15-FR   France
   Affiliated Hospital of Guangdong Medical University
      2020   Phase 0   ChiCTR2100041655   China
   Assistance Publique - Hôpitaux de Paris
      2020   Phase 2   NCT03970577   France
      2009   Phase 3   NCT01197040   France
   Astellas Pharma Global Development, Inc.
      2017   Phase 2   NCT02921789   Canada;United States
   Cairo University
      2018   -   JPRN-UMIN000035961   Africa
   Department of Nephrology, The First Affiliated Hospital of Bengbu Medical College
      2017   Phase 4   ChiCTR1900027627   China
   Hoffmann-La Roche
      2023   Phase 3   NCT05627557   Belgium;Brazil;China;France;Germany;Italy;Japan;Poland;Spain;Turkey (Türkiye);United States
   Institute of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
      2006   -   ChiCTR-OPN-17012789   China
   Jianhua Zhou
      2023   Phase 4   NCT05772871   China
   Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University
      2011   -   ChiCTR-TRC-11001454   China
   Longhua Hospital Affiliated to Shanghai University of TCM
      2008   Phase 1 study   ChiCTR-TRC-08000098   China
   Nanjing University School of Medicine
      2014   -   NCT02298335   China
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1986   Phase 2   NCT00001212   United States
   Peking Union Medical College Hospital
      2021   Phase 3   NCT04745728   China
   Rabin Medical Center
      2016   Phase 4   NCT02649413   Israel
   Radboud University
      2018   Phase 3   NCT03298698   Netherlands
   Renmin Hospital of Wuhan University
      2024   Phase 2   NCT06614985   China
   Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg and its Commercial
      2015   Phase 3   EUCTR2014-001991-76-DE   Germany
   Shanghai Children's Hospital
      2020   Phase 0   ChiCTR2000037014   China
   Shanghai Jiaotong University Affiliated Ruijin Hospital
      2008   -   ChiCTR-TRC-10001024   China
   Shanghai Jiaotong University School of Medicine Renji Hospital Nephrology
      2017   -   ChiCTR-INR-17010676   China
   The Children's Hospital Zhejiang University School of Medicine
      2022   -   ChiCTR2300076574   China
   The First Affiliated Hospital of Bengbu Medical College
      2020   Phase 4   ChiCTR2000033766   China
   The First Affiliated Hospital, College of Medicine, Zhejiang University
      2024   Phase 4   ChiCTR2400081948   China
   The Hospital for Sick Children
      2024   Phase 3   NCT06635720   Canada
   Treatment center of kidney disease, 281th hospital of PLA
      2009   Phase 1 study   ChiCTR-TQR-12002602   China
   Wenhu Liu
      2018   -   NCT03466801   China
   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
      2018   -   NCT03864250   China
      2018   -   NCT03549663   China
   the First Affiliated Hospital of Third Military Medical University
      2018   -   ChiCTR1800014719   China
Prednisone 0,5 MG/KG orally ON alternate days
   Radboud University
      2002   Phase 2/Phase 3   NCT00135967   Netherlands
Prednisone 30 MG
   Rabin Medical Center
      2014   Phase 4   NCT02216747   Israel
Prednisone 45 MG
   Rabin Medical Center
      2014   Phase 4   NCT02216747   Israel
Prednisone 60 MG/meter square body surface area
   Rabin Medical Center
      2014   Phase 4   NCT02216747   Israel
Prednisone acetate
   The Second Affiliated Hospital of Nanchang University
      2023   -   ChiCTR2300076737   China
Prednisone, ciclosporin and mycophenolate mofetil
   Beijing Friendship Hospital
      2020   Phase 4   NCT04424862   China
Prednisone, FK506, MMF
   Xi’an Jiaotong University College of Medicine
      2009   -   NCT00956059   China
Prednisone,methylprednisone and cyclophosphamide
   Beijing Friendship Hospital
      2023   -   NCT06245707   China
Privigen 100 MG/ML solution pour perfusion
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2018   Phase 3   EUCTR2017-000826-36-FR   France
Prograf
   Astellas Pharma Korea, Inc.
      -   -   EUCTR2015-001039-18-Outside-EU/EEA   Korea, Republic of
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-003233-38-IT   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
QT-219CX
   The Children's Hospital of Zhejiang University School of Medicine
      2026   Early Phase 1   NCT07586267   China
R3r01
   River 3 Renal Corp.
      2022   Phase 2   NCT05267262   Belgium;France;Germany;Netherlands;United Kingdom;United States
   River 3 Renal, Corporation
      2022   Phase 2   EUCTR2021-004192-13-NL   Belgium;France;Germany;Netherlands;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004192-13-BE   Belgium;France;Germany;Netherlands;United Kingdom;United States
      -   Phase 2   EUCTR2021-004192-13-FR   Belgium;France;Germany;Netherlands;United Kingdom;United States
Ramipril
   The Second Affiliated Hospital of Army Medical University
      2025   -   ChiCTR2500108026   China
RE-021
   RETROPHIN, INC
      2018   Phase 3   EUCTR2016-005141-23-IT   Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Korea, Republic of;New Zealand;Poland;Portugal;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
   Retrophin, Inc
      2015   Phase 2   EUCTR2014-002358-38-BE   Belgium;Czech Republic;Italy
      2014   Phase 2   EUCTR2014-002358-38-IT   Belgium;Czech Republic;Italy
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-005141-23-HU   Australia;Belgium;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Italy;Korea, Republic of;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2016-005141-23-GB   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2016-005141-23-ES   Australia;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Poland;South Africa;Spain;Taiwan;United Kingdom;United States
      2013   -   NCT01622738   United States
   TRAVERE THERAPEUTICS, INC
      2022   Phase 2   EUCTR2021-000621-27-IT   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2016-005141-23-HR   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2016-005141-23-EE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
   Travere Therapeutics, Inc.
      2022   Phase 2   EUCTR2021-000621-27-SE   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-000621-27-NL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-000621-27-FR   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2021   Phase 2   EUCTR2021-000621-27-ES   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   EUCTR2016-005141-23-PL   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2015   Phase 2   EUCTR2014-002358-38-CZ   Belgium;Czech Republic;Czechia;Italy
      2014   Phase 2   NCT01613118   Belgium;Czechia;Italy;United States
      -   Phase 2   EUCTR2021-000621-27-PL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 2   EUCTR2021-000621-27-DE   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
Repagermanium
   Dimerix Bioscience Pty Ltd
      2022   Phase 3   EUCTR2021-004174-64-FR   Argentina;Australia;Brazil;Denmark;France;Hong Kong;Korea, Republic of;New Zealand;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-004174-64-ES   Argentina;Australia;Brazil;Denmark;France;Hong Kong;Korea, Republic of;New Zealand;Spain;Taiwan;United Kingdom;United States
      2022   Phase 3   EUCTR2021-004174-64-DK   Argentina;Australia;Brazil;Denmark;France;Hong Kong;New Zealand;Spain;Taiwan;United Kingdom;United States
Repository corticotropin injection
   Mallinckrodt
      2011   Phase 4   NCT01386554   Canada;Chile;Mexico;Turkey;United States
Rilzabrutinib
   Sanofi
      2024   Phase 2   NCT06500702   Argentina;Australia;Brazil;Canada;Chile;China;Czechia;France;Germany;Greece;Hungary;Italy;Mexico;Netherlands;Poland;Portugal;Slovakia;Spain;Taiwan;Turkey (Türkiye);United Kingdom;United States
Ripertamab
   Mao Jianhua
      2026   -   NCT07388810   China
Rituximab
   ???
      2020   Phase 4   ChiCTR2000031963   China
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
      2019   Phase 2   EUCTR2018-003437-15-FR   France
   Ain Shams University
      2022   Phase 2/Phase 3   NCT05553496   -
   Akihito Tanaka
      2023   Phase 3   JPRN-jRCT2041230037   -
   Alice Bertaina
      2023   Phase 1/Phase 2   NCT05508009   United States
   Assistance Publique - Hôpitaux de Paris
      2020   Phase 2   NCT03970577   France
      2012   Phase 3   NCT01508468   France
   Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
      2012   Phase 3   NCT03018535   Italy
   Beijing Friendship Hospital
      2023   -   NCT06245707   China
      2022   -   NCT05782933   China
   CHU de LIMOGES
      2013   Phase 3   EUCTR2009-018266-35-BE   Belgium;France
      2010   Phase 3   EUCTR2009-018266-35-FR   Belgium;France
   Cambridge University Hospitals NHS Foundation Trust
      2019   Phase 3   EUCTR2018-004611-50-GB   United Kingdom
   Centre Hospitalier Universitaire de Nice
      2020   Phase 2   NCT03804359   France
   Cerium Pharmaceuticals, Inc.
      2023   Phase 3   NCT05696613   Canada;India;United States
   Children's Hospital of Chongqing Medical University
      2023   Phase 2   NCT05843968   China
   Children's Hospital of Fudan University
      2025   Phase 3   NCT05850546   China
      2021   Phase 2   NCT04783675   China
      2020   Phase 3   NCT04531865   China
   Children's Hospital,Zhejiang University School of Medicine
      2026   -   ChiCTR2600126859   China
   Department of Medicine, Kidney Center, Tokyo Women's Medical University
      2011   Phase 3   JPRN-UMIN000005231   Japan
   Department of Nephrology, Army Medical Center of PLA
      2022   Phase 4   ChiCTR2200065822   China
   Department of Pediatrics, Kobe University Graduate School of Medicine
      2013   -   JPRN-UMIN000009411   Japan
   Fundacion Renal Iñigo Alvarez Toledo
      2015   -   EUCTR2013-000226-55-NL   Netherlands;Spain
   George W. Burke
      2012   Phase 3   NCT01164098   United States
   Graduate School Medical Sciences, Kyushu University
      2013   -   JPRN-UMIN000017470   Japan
   Hayashi Terumasa
      2015   Phase 4   JPRN-jRCTs051180180   -
   Hospital Universitario 12 de Octubre
      2014   Phase 3   NCT01955187   Spain
   IRCCS ISTITUTO GIANNINA GASLINI
      -   Phase 2   EUCTR2015-000624-28-IT   Italy
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2009   Phase 3   EUCTR2008-006750-17-IT   Italy
   ISTITUTO GIANNINA GASLINI
      2008   -   EUCTR2008-004486-26-IT   Italy
   Istituto Giannina Gaslini
      2015   Phase 2   NCT02394119   Italy
      2013   Phase 3   NCT04494438   Italy
   Japanese Study Group of Kidney Disease in Children
      2015   -   JPRN-UMIN000014895   Japan
      2015   Phase 3   JPRN-UMIN000014347   Japan
   Jiangsu Province People's Hospital
      2019   Phase 4   ChiCTR1900026382   China
   Liuzhou Hospital of Guangzhou Women and Children’s Medical Center
      2025   Phase 4   ChiCTR2400094085   China
   Mario Negri Institute for Pharmacological Research
      2009   Phase 3   NCT00981838   Italy
   Mayo Clinic
      2013   Phase 2   NCT01573533   Canada;United States
      2011   Phase 2/Phase 3   NCT01180036   Canada;United States
      2006   Phase 0   NCT00405340   United States
      2004   Phase 2/Phase 3   NCT00425217   United States
   Nanjing General hospital of Nanjing militray command
      2011   -   ChiCTR-ONC-10001125   China
   National Institute of Allergy and Infectious Diseases (NIAID)
      2020   Phase 2   NCT03949855   Canada;United States
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2008   Phase 2   NCT00550342   United States
   National University Health System, Singapore
      2008   Phase 3   NCT03501459   Singapore
   Nationwide Children's Hospital
      2015   Phase 3   NCT02390362   United States
   Nilratan Sircar Medical College
      2019   Phase 3   NCT03899103   India
      2015   Phase 3   NCT02438982   India
      2015   Phase 4   NCT02382575   India
   Novartis Farmacéutica, S.A.
      2019   Phase 2   EUCTR2019-001734-34-ES   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States
   Novartis Pharma AG
      2020   Phase 2   EUCTR2019-001734-34-NL   Argentina;China;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-GB   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-FR   Argentina;Czech Republic;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;United Kingdom;United States
      2019   Phase 2   EUCTR2019-001734-34-DE   Argentina;China;Czech Republic;Czechia;France;Germany;India;Netherlands;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
   Novartis Pharmaceuticals
      2019   Phase 2   NCT04154787   Argentina;China;Czechia;France;Germany;India;Netherlands;Singapore;Spain;Taiwan;United Kingdom;United States
   Nozu Kandai
      2015   Phase 3   JPRN-jRCTs051180081   -
   Osaka General Medical Center
      2015   Phase 4   JPRN-UMIN000019844   Japan
   Peking Union Medical College Hospital
      2021   Phase 3   NCT04745728   China
      2021   Phase 3   NCT04743739   China
   Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
      2020   Phase 4   ChiCTR2000033540   China
   Peking University Third Hospital
      2022   -   ChiCTR2200057381   China
   Qianfoshan Hospital
      2023   -   NCT05667909   -
   Radboud University
      2018   Phase 3   NCT03298698   Netherlands
   Radboud University Nijmegen Medical Center
      2017   Phase 3   EUCTR2017-003366-27-NL   Netherlands
   Saitama Medical University Department of Nephrology
      2014   -   JPRN-UMIN000014355   Japan
   Seoul National University Childrens Hospital
      2012   Phase 2/Phase 3   NCT01716442   Korea, Republic of
   Shanghai Children's Hospital
      2022   Phase 0   ChiCTR2200057174   China
   Shanghai Children’s Hospital
      2025   Phase 0   ChiCTR2500101933   China
   Shanghai Dongfang Hospital
      2021   Phase 0   ChiCTR2100049205   China
   Shanghai JMT-Bio Inc.
      2025   Phase 2   NCT07029139   -
   Shanghai Jiaotong University School of Medicine Renji Hospital Nephrology
      2017   -   ChiCTR-INR-17010676   China
   Shoichi Maruyama MD PhD
      2023   Phase 3   NCT05914155   Japan
   The Children's Hospital of Zhejiang University School of Medicine
      2023   Phase 3   NCT05734794   China
   The First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital
      2021   -   ChiCTR2100050205   China
   The First Affiliated Hospital of Xiamen University
      2020   -   NCT06530004   China
   The First Affiliated Hospital, Sun Yat-Sen University
      2021   Phase 4   ChiCTR2100046611   China
      2020   Phase 4   ChiCTR2000040799   China
   The Second Affiliated Hospital of Nanchang University
      2023   -   ChiCTR2300076737   China
   Tokyo Metropolitan Geriatric Hospital
      2016   -   JPRN-UMIN000022150   Japan
   University Hospital, Limoges
      2010   Phase 2/Phase 3   NCT01268033   Belgium;France
   University of Minnesota
      2019   Early Phase 1   NCT03763643   United States
   West China Hospital of Sichuan University
      2025   -   ChiCTR2500104136   China
   West China Hospital, Sichuan University
      2025   -   ChiCTR2500103206   China
   Wuhan Children's Hospital
      2021   -   NCT07049172   China
   Xiangya Hospital, Central South University
      2025   Phase 4   ChiCTR2600124282   China
   Xijing Hospital
      2022   Phase 0   ChiCTR2200064268   China
   Xinqiao Hospital
      2020   Phase 4   ChiCTR2000032523   China
   Zhujiang Hospital
      2016   Phase 2   NCT02966717   China
Rituximab biosimilar
   Istituto Giannina Gaslini
      2020   Phase 2   NCT04585152   Italy
      2019   Phase 2   NCT04402580   Italy
Rituximab biosimilar ABP 798
   Istituto Giannina Gaslini
      2023   Phase 2   NCT05704400   Italy
Rituximab combined with corticosteroids
   First Affiliated Hospital, Sun Yat-Sen University
      2024   Phase 4   NCT05514015   China
Rituximab combined with tacrolimus induction + rituximab maintenance
   RenJi Hospital
      2022   -   NCT05532111   -
   Renji Hospital Affiliated to Shanghai jiao tong university school of medicine
      2022   -   ChiCTR2200063389   China
Rituximab combined with tacrolimus induction + tacrolimus maintenance
   RenJi Hospital
      2022   -   NCT05532111   -
   Renji Hospital Affiliated to Shanghai jiao tong university school of medicine
      2022   -   ChiCTR2200063389   China
Rituximab infusion
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2010   Phase 2   NCT00977977   United States
Rituximab injection
   Centre Hospitalier Universitaire de Nice
      2025   Phase 3   NCT06341205   France
Rituximab, cyclophosphamide, and corticosteroids
   St. Petersburg State Pavlov Medical University
      2018   -   NCT05679336   Russian Federation
Rivaroxaban
   Peking Union Medical College Hospital, Chinese Academy of Medical Science
      2021   Phase 4   ChiCTR2000029081   China
   Shanghai First People's Hospital
      2021   Phase 4   ChiCTR2000036449   China
Rivaroxaban 10 MG
   Beijing Friendship Hospital
      2024   Phase 4   NCT07404436   China
Rixathon® 500 MG
   APHP
      2023   Phase 3   EUCTR2022-003336-59-FR   France
RO0485337
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-003233-38-IT   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-003233-38-PL   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
      2021   Phase 3   EUCTR2020-003233-38-FR   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
RO5072759
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-003233-38-IT   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
   F. Hoffman-La Roche Ltd
      2023   Phase 3   EUCTR2022-000369-42-PL   Belgium;Brazil;France;Germany;Italy;Poland;Spain;Turkey;United States
   F. Hoffman-La Roche Ltd.
      2023   Phase 3   EUCTR2022-000369-42-FR   Belgium;Brazil;France;Germany;Italy;Poland;Spain;Turkey;United States
      2023   Phase 3   EUCTR2022-000369-42-DE   Belgium;Brazil;France;Germany;Italy;Poland;Spain;Turkey;United States
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-003233-38-PL   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
      2021   Phase 3   EUCTR2020-003233-38-FR   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2021   Phase 2   EUCTR2021-004864-81-IT   Italy
Rosiglitazone
   North Shore Long Island Jewish Health System
      2005   Phase 1   NCT00193648   United States
Sacubitril
   China-Japan Friendship Hospital
      2021   Phase 4   ChiCTR2100050967   China
Sample collection
   Mario Negri Institute for Pharmacological Research
      2026   -   NCT07416942   Italy
Sandimmun neoral
   AIBILI - Associação para Investigação Biomédica e Inovação em Luz e Imagem
      2013   -   EUCTR2013-001542-34-PT   Portugal
Saquinavir
   OSPEDALE POLICLINICO S. MATTEO
      2009   -   EUCTR2009-013484-19-IT   Italy
Serine
   The Children's Hospital Zhejiang University School of Medicine
      2022   -   ChiCTR2300076574   China
   The Children's Hospital, Zhejiang University School of Medicine
      2022   -   ChiCTR2300076577   China
Serum protein ,kidney function ,liver function.,serum cholesterol
   Assiut University
      2018   -   NCT03219684   -
SG301 subcutaneous injection
   Mao Jianhua
      2025   Phase 2   NCT07087314   China
Short-term course (12 week) glucocorticoid regimen
   First Affiliated Hospital of Wenzhou Medical University
      2026   Phase 4   NCT07151456   China
   The First Affiliated Hospital of Wenzhou Medical University
      2026   Phase 4   ChiCTR2500111892   China
SHR-2173 injection
   Guangdong Hengrui Pharmaceutical Co., Ltd
      2025   Phase 2   NCT07289763   China
SHR1459 high dose
   Reistone Biopharma Company Limited
      2021   Phase 2   NCT05136456   China
SHR1459 LOW dose
   Reistone Biopharma Company Limited
      2021   Phase 2   NCT05136456   China
Single infusion OF obinutuzumab
   Assistance Publique - Hôpitaux de Paris
      2023   Phase 2/Phase 3   NCT05786768   France
Single infusion OF rituximab
   Assistance Publique - Hôpitaux de Paris
      2023   Phase 2/Phase 3   NCT05786768   France
Sinomenine
   Macau University of Science and Technology
      2021   Phase 4   ChiCTR2100047996   China
Sirolimus
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2002   Phase 2   NCT00050713   United States
      2002   Phase 2   NCT00040508   United States
   Renal Division, Peking University First Hospital
      2017   -   ChiCTR-INR-17012212   China
SK-09
   Consun Pharmaceutical Group
      2025   Phase 1   NCT07267026   Australia
SNP-acth (1-39) GEL
   Cerium Pharmaceuticals, Inc.
      2023   Phase 3   NCT05696613   Canada;India;United States
Solondo
   Astellas Pharma Korea, Inc.
      -   -   EUCTR2015-001039-18-Outside-EU/EEA   Korea, Republic of
Somatropin
   Pharmacia & Upjohn S.A.
      -   -   EUCTR2014-004104-30-Outside-EU/EEA   France
Sparsentan
   RETROPHIN, INC
      2018   Phase 3   EUCTR2016-005141-23-IT   Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Democratic People's Republic of;Korea, Republic of;New Zealand;Poland;Portugal;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
   Retrophin, Inc
      2015   Phase 2   EUCTR2014-002358-38-BE   Belgium;Czech Republic;Italy
      2014   Phase 2   EUCTR2014-002358-38-IT   Belgium;Czech Republic;Italy
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-005141-23-HU   Australia;Belgium;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Italy;Korea, Republic of;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 3   EUCTR2016-005141-23-ES   Australia;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Korea, Republic of;Poland;South Africa;Spain;Taiwan;United Kingdom;United States
   TRAVERE THERAPEUTICS, INC
      2022   Phase 2   EUCTR2021-000621-27-IT   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Travere Therapeutics, Inc.
      2025   Phase 4   NCT07219121   United States
      2022   Phase 2   EUCTR2021-000621-27-SE   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-000621-27-NL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2022   Phase 2   EUCTR2021-000621-27-FR   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2021   Phase 2   NCT05003986   Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2021   Phase 2   EUCTR2021-000621-27-ES   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2018   Phase 3   NCT03493685   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;New Zealand;Poland;Portugal;South Korea;Spain;Sweden;Taiwan;United Kingdom;United States
      2015   Phase 2   EUCTR2014-002358-38-CZ   Belgium;Czech Republic;Czechia;Italy
      2014   Phase 2   NCT01613118   Belgium;Czechia;Italy;United States
      -   Phase 2   EUCTR2021-000621-27-PL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      -   Phase 2   EUCTR2021-000621-27-DE   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
Sparsentan/OVER-encapsulated sparsentan tablet
   Travere Therapeutics, Inc.
      2018   Phase 3   EUCTR2016-005141-23-PL   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
Sparsentan/OVER-encapsulated sparsentan tabletproduct code: RE-021pharmaceutical form: capsule, hardinn or proposed INN: sparsentancas number: 254740-64-2current sponsor code: RE-021other descriptive name: sparsentanconcentration unit: MG milligram(S)concentration type: equalconcentration number: 200-
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2016-005141-23-DE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
Sparsentan/OVER-encapsulated sparsentan tablets
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-005141-23-GB   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2016-005141-23-HR   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2016-005141-23-EE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
Sparsentan/OVER-encapsulated sparsentan tabletsproduct code: RE-021pharmaceutical form: capsule, hardcas number: 254740-64-2concentration unit: MG milligram(S)concentration type: equalconcentration number: 200-
   Travere Therapeutics Inc.
      2018   Phase 3   EUCTR2016-005141-23-DK   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
Sparsentan/OVER-encapsulated sparsentan tabletsproduct code: RE-021pharmaceutical form: capsule, hardinn or proposed INN: sparsentancas number: 254740-64-2concentration unit: MG milligram(S)concentration type: equalconcentration number: 200-
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2016-005141-23-SE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2016-005141-23-PT   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
      2019   Phase 3   EUCTR2016-005141-23-BE   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
Sparsentan/OVER-encapsulated sparsentan tabletsproduct code: RE-021pharmaceutical form: capsule, hardinn or proposed INN: sparsentancas number: 254740-64-2current sponsor code: RE-021other descriptive name: sparsentanconcentration unit: MG milligram(S)concentration type: equalconcentration number: 200-
   Travere Therapeutics Inc.
      2018   Phase 3   EUCTR2016-005141-23-CZ   Argentina;Australia;Belgium;Brazil;Canada;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;New Zealand;Poland;Portugal;Spain;Sweden;Taiwan;United Kingdom;United States
Sparsentanproduct code: RE-021pharmaceutical form: capsule, hardinn or proposed INN: sparsentancas number: 254740-64-2current sponsor code: RE-021other descriptive name: sparsentanconcentration unit: MG milligram(S)concentration type: equalconcentration number: 200-
   Retrophin, Inc.
      2018   Phase 3   EUCTR2016-005141-23-FR   Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Italy;Korea, Republic of;Poland;Portugal;South Africa;Spain;Sweden;Taiwan;United Kingdom;United States
Spironolactone
   Khushnood Maqbool
      2026   -   ChiCTR2500113572   Pakistan
Standard OF care IST
   Biogen
      2025   Phase 3   NCT06962800   Argentina;Australia;Brazil;Canada;China;India;Japan;Malaysia;South Korea;Taiwan;United States
Standard prednisolone treatment
   Institute of Child Health
      2003   Phase 4   NCT00308321   United Kingdom
Standard therapy
   Ain Shams University
      2023   Phase 4   NCT05966818   -
   Mansoura University
      2025   Phase 2/Phase 3   NCT07214818   Egypt
Steroid
   Children's Hospital of Chongqing Medical University
      2025   Phase 4   ChiCTR2500109037   China
   Division of Kidney and Dialysis, Department of Internal Medicine,Hyogo College of Medicine
      2007   Phase 4   JPRN-UMIN000001099   Japan
   Huashan Hospital, Fudan University
      2026   Phase 4   ChiCTR2600125299   China
   Mao Jianhua
      2023   Phase 3   NCT06079788   China
   Nozu Kandai
      2019   Phase 3   JPRN-jRCT2051190019   -
   Shanghai Children's Hospital
      2025   Phase 0   ChiCTR2500103238   China
      2022   Phase 0   ChiCTR2200057174   China
      2020   Phase 0   ChiCTR2000037014   China
   Sun Yat-sen University
      2014   Phase 2   NCT02173106   China
   The Children's Hospital of Zhejiang University School of Medicine
      2023   Phase 3   NCT05734794   China
   The study group of treatment for aged patients with nephrotic syndrome.
      2012   -   JPRN-UMIN000008919   Japan
   Tianjin First Central Hospital
      2017   -   ChiCTR-IPR-17011702   China
Surovatamig
   AstraZeneca
      2026   Phase 2   NCT07571746   Belgium;France;Germany;Italy;Poland;Spain;United Kingdom;United States
Synacthen depot 1MG
   Radboud University Nijmegen Medical Center
      2008   -   EUCTR2008-001647-19-NL   Netherlands
Tacrolimus
   Astellas Pharma Korea, Inc.
      2012   Phase 4   NCT01763580   Korea, Republic of
      -   -   EUCTR2015-001039-18-Outside-EU/EEA   Korea, Republic of
   Baoji Central Hospital
      2016   -   ChiCTR-IPR-16008344   China
   BeOne Medicines
      2023   Phase 2/Phase 3   NCT05707377   Argentina;Brazil;Canada;China;Czechia;Italy;Mexico;Poland;Russia;Spain;Turkey (Türkiye);United Kingdom;United States
   Biogen
      2025   Phase 3   NCT06962800   Argentina;Australia;Brazil;Canada;China;India;Japan;Malaysia;South Korea;Taiwan;United States
   Children's Hospital of Chongqing Medical University
      2025   Phase 4   ChiCTR2500109037   China
   Children's Hospital, Zhejiang University School of Medicine
      2019   Phase 4   ChiCTR1900022943   China
      2019   Phase 4   ChiCTR1900022724   China
   Department of Nephrology and Hypertension, Saitama Medical Center,Saitama Medical University
      2012   -   JPRN-UMIN000007089   Japan
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 3   EUCTR2020-003233-38-IT   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
   F.Hoffmann-La Roche Ltd
      2021   Phase 3   EUCTR2020-003233-38-PL   Argentina;Brazil;Canada;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
      2021   Phase 3   EUCTR2020-003233-38-FR   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russian Federation;Spain;Turkey;Ukraine;United States
   Fundacion Renal Iñigo Alvarez Toledo
      2015   -   EUCTR2013-000226-55-NL   Netherlands;Spain
   Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
      2008   -   EUCTR2007-005410-39-ES   Spain
   Hoffmann-La Roche
      2021   Phase 3   NCT04629248   Argentina;Brazil;China;France;Israel;Italy;Peru;Poland;Russia;Spain;Turkey (Türkiye);Ukraine;United States
   Hospital Universitario 12 de Octubre
      2014   Phase 3   NCT01955187   Spain
   Imperial College NHS trust
      2009   Phase 4   EUCTR2009-014292-52-GB   United Kingdom
   Japanese Study Group of Kidney Disease in Children
      2010   -   JPRN-UMIN000004204   Japan
   Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University
      2011   -   ChiCTR-TRC-11001454   China
   Matsuda Naoto
      2026   Phase 3   JPRN-jRCT2011250054   Japan;USA
   Nanjing University School of Medicine
      2006   -   NCT00302536   China
      2006   -   NCT00302523   China
   Nilratan Sircar Medical College
      2015   Phase 3   NCT02438982   India
      2015   Phase 4   NCT02382575   India
   People’s Hospital of Songzi
      2022   -   ChiCTR2200058661   China
   Qianfoshan Hospital
      2023   -   NCT05667922   -
   Second Hospital of Jilin University
      2004   -   ChiCTR-TRC-09000539   China
   Seoul National University Hospital
      2010   Phase 4   NCT01162005   Korea, Republic of
   Shandong University
      2012   Phase 4   NCT03347357   -
   Shanghai Changzheng Hospital
      2009   -   ChiCTR-TRC-10000945   China
   Shanghai Children's Hospital
      2025   Phase 0   ChiCTR2500103238   China
   Shenzhen Second People's Hospital
      2020   Phase 4   ChiCTR2000032422   Chiina
   Sichuan Provincial People's Hospital
      2018   -   ChiCTR1800016140   China
   Southwest Hospital, the First Affiliated Hospital of Army Medical University
      2020   Phase 4   ChiCTR2000031003   China
   Sun Yat-sen University
      2011   Phase 3   NCT01309477   China
      2006   Phase 3   NCT00615667   -
   The Children's Hospital of Zhejiang University School of Medicine
      2019   Phase 4   NCT04048161   China
   The First Affiliated Hospital of Bengbu Medical College
      2020   Phase 4   ChiCTR2000033766   China
   The First Affiliated Hospital of Dalian Medical University
      2013   -   ChiCTR-RCH-13003503   China
   The First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital
      2021   -   ChiCTR2100050205   China
   The First Affiliated Hospital of the Air Force Medical University
      2025   Phase 4   ChiCTR2500112773   China
   The First Affiliated Hospital, College of Medicine, Zhejiang University
      2024   Phase 4   ChiCTR2400081948   China
      2022   Phase 4   ChiCTR2200056304   China
   The Second Affiliated Hospital of Nanchang University
      2023   -   ChiCTR2300076737   China
   The Second Affiliated Hospital of Xi'an Jiaotong University
      2021   -   ChiCTR2100048518   China
   The Seventh Affiliated Hospital of Sun Yat sen University
      2023   Phase 4   ChiCTR2200067000   China
   The Third Xiangya Hospital of Central South University
      2019   -   NCT04045171   -
   The first affiliated hospital of Anhui Medical University
      2010   -   ChiCTR-OOC-15007028   China
   Vertex Pharmaceuticals Incorporated
      2025   Phase 2/Phase 3   NCT07204275   Australia;Brazil;China;Czechia;Germany;Hungary;Ireland;Italy;Japan;South Korea;Spain;United Kingdom;United States
   Wuhan Children's Hospital
      2021   -   NCT07049172   China
      2019   Phase 0   ChiCTR1900022334   China
   Xijing Hospital
      2022   Phase 0   ChiCTR2200064268   China
   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
      2018   -   NCT03864250   China
      2018   -   NCT03549663   China
   Xinqiao Hospital
      2020   Phase 4   ChiCTR2000032523   China
   the First Affiliated Hospital of Third Military Medical University
      2018   -   ChiCTR1800014719   China
Tacrolimus &entecavir
   Guangdong General Hospital
      2017   Phase 4   NCT03062813   China
Tacrolimus capsules
   Astellas Pharma Global Development, Inc.
      2017   Phase 2   NCT02921789   Canada;United States
Tacrolimus combined with prednisone
   Peking University
      2004   Phase 2/Phase 3   NCT00362531   -
Tacrolimus FOR THE treatment OF IMN
   Qianfoshan Hospital
      2023   -   NCT05797038   -
Targeted nursing care
   Wuhan Children's Hospital
      2021   -   NCT07049172   China
Telitacicept
   Children's Hospital of Chongqing Medical University
      2025   Phase 4   ChiCTR2500109037   China
   Chinese PLA General Hospital
      2023   Phase 0   ChiCTR2300077036   China
   Qilu Hospital of Shandong University
      2022   Phase 4   ChiCTR2200055179   China
   Renmin Hospital of Wuhan University
      2024   Phase 2   NCT06614985   China
   The Children's Hospital of Zhejiang University School of Medicine
      2023   Phase 3   NCT06125405   China
   The First Affiliated Hospital of Zhengzhou University
      2026   -   ChiCTR2600115890   China
   The First Affiliated Hospital of the Air Force Medical University
      2025   Phase 4   ChiCTR2500112773   China
Telmisartan
   The Second Affiliated Hospital of Army Medical University
      2025   -   ChiCTR2500108026   China
Tetracosactide hexacetaat
   Radboud University
      2008   Phase 2   NCT00694863   Netherlands
THE comprehensive treatment regimen OF traditional chinese medicine
   Shanghai University of Traditional Chinese Medicine
      2010   -   NCT01799460   China
THE immunosuppressive agents
   Shanghai University of Traditional Chinese Medicine
      2010   -   NCT01799460   China
Tissue sample
   Centre Hospitalier Universitaire de Nice
      2020   -   NCT04174066   France
Tolvaptan
   Shonan Kamakura General Hospital
      2013   -   JPRN-UMIN000011763   Japan
   Toyama University Hospital
      2016   -   JPRN-UMIN000022422   Japan
Torasemide
   Division of Nephrology, Guangdong General Hospital
      2015   -   ChiCTR-IPR-15006391   China
Total body irradiation
   Alice Bertaina
      2023   Phase 1/Phase 2   NCT05508009   United States
Tripterygium wilfordii
   Department of Nephrology, Sichuan Provincial People's Hospital
      2021   -   ChiCTR2100048382   China
   Nanjing University School of Medicine
      2009   -   NCT00801463   China
   Shanxi Hospital of Traditional Chinese Medicine
      2022   Phase 0   ChiCTR2200062685   China
   Zhi-Hong Liu, M.D.
      2010   -   NCT01161459   China
TRU-015
   Wyeth is now a wholly owned subsidiary of Pfizer
      2007   Phase 1   NCT00479622   United States
Truxima
   CHU de Nice
      2019   Phase 2   EUCTR2018-002476-40-FR   France
Truximab
   CHU de Nice
      2019   Phase 2   EUCTR2018-002476-40-FR   France
Ucar T-cell
   The Children's Hospital of Zhejiang University School of Medicine
      2026   Early Phase 1   NCT07507201   China
      2025   Phase 1   NCT07305116   China
Urbason*IM EV 1F 250MG+1F 5ML
   AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
      2012   -   EUCTR2011-006115-59-IT   Italy
Valproic acid
   Universitair Ziekenhuis Brussel
      2016   Phase 2/Phase 3   NCT02896270   Belgium
Valsartan
   China-Japan Friendship Hospital
      2021   Phase 4   ChiCTR2100050967   China
   Columbia University
      2009   Phase 4   NCT01129557   United States
   Novartis Pharmaceuticals
      2011   Phase 1   NCT01447485   Japan
      -   Phase 1   EUCTR2015-004445-10-Outside-EU/EEA   Japan
   Shijiazhuang Nephropathy Hospital
      2017   -   ChiCTR-INR-17012070   China
   The People's Hospital of Guangxi Zhuang Autonomous Region
      2019   -   ChiCTR1800020241   China
   The Second Affiliated Hospital of Army Medical University
      2025   -   ChiCTR2500108026   China
VB119
   Tenet Medicines
      2022   Phase 2   NCT05441826   United States
      2021   Phase 1/Phase 2   NCT04652570   Mexico;United Kingdom;United States
VIS171
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2025   Phase 1   NCT06799520   Bulgaria;Moldova;Romania;Spain
Vitamin D
   Guangzhou women and children's medical center
      2022   Phase 4   ChiCTR2200055790   China
   The People's Hospital of Guangxi Zhuang Autonomous Region
      2019   -   ChiCTR1800020241   China
Vitamin K 2
   Ain Shams University
      2025   -   NCT07206537   Egypt
Voclosporin
   Aurinia Pharmaceuticals Inc.
      2018   Phase 2   NCT03598036   Dominican Republic;United States
VX-147
   Vertex Pharmaceuticals Incorporated
      2023   Phase 1   NCT05955872   United States
      2020   Phase 2   NCT04340362   France;Puerto Rico;United Kingdom;United States
      2020   Phase 2   EUCTR2020-000185-42-GB   France;United Kingdom;United States
      2020   Phase 2   EUCTR2020-000185-42-FR   France;United Kingdom;United States
VX147
   Vertex Pharmaceuticals Incorporated
      2020   Phase 2   EUCTR2020-000185-42-GB   France;United Kingdom;United States
      2020   Phase 2   EUCTR2020-000185-42-FR   France;United Kingdom;United States
WAL0921
   Walden Biosciences
      2024   Phase 2   NCT06466135   Australia;India;Malaysia;South Korea;Sri Lanka;United Kingdom;United States
Warfarin
   Peking Union Medical College Hospital, Chinese Academy of Medical Science
      2021   Phase 4   ChiCTR2000029081   China
   Shanghai First People's Hospital
      2021   Phase 4   ChiCTR2000036449   China
   The Japanese Pediatric IgA Nephropathy of Treatment Study Group
      1998   -   JPRN-C000000375   Japan
   Zhejiang Provincial People's Hospital
      2017   Phase 4   ChiCTR-IPR-17013428   China
Warfarin sodium
   Beijing Friendship Hospital
      2024   Phase 4   NCT07404436   China
YK012
   Excyte Biopharma Ltd
      2026   Phase 1   NCT07234474   -
      2025   Phase 1   NCT06982729   China
Zanubrutinib
   BeOne Medicines
      2023   Phase 2/Phase 3   NCT05707377   Argentina;Brazil;Canada;China;Czechia;Italy;Mexico;Poland;Russia;Spain;Turkey (Türkiye);United Kingdom;United States
Zestril
   Hopital Erasme
      2006   Phase 4   EUCTR2005-004469-40-BE   Belgium
      2006   Phase 4   EUCTR2005-004460-22-BE   Belgium
Zinc supplementation plus standard treatment
   Muhammad Aamir Latif
      2024   -   NCT06860620   Pakistan
Zuberitamab 1000MG
   BioRay Pharmaceutical Co., Ltd.
      2024   Phase 2   NCT06642909   China
Zuberitamab 600MG
   BioRay Pharmaceutical Co., Ltd.
      2024   Phase 2   NCT06642909   China